Original Article
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
N Engl J Med 2003; 349:2483-2494December 25, 2003
- Abstract
Background
Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both.
Methods
We subjected purified plasma cells from the bone marrow of patients with newly diagnosed multiple myeloma and control subjects to oligonucleotide microarray profiling and biochemical and immunohistochemical analyses to identify molecular determinants of osteolytic lesions.
Results
We studied 45 control subjects, 36 patients with multiple myeloma in whom focal lesions of bone could not be detected by magnetic resonance imaging (MRI), and 137 patients in whom MRI detected such lesions. Different patterns of expression of 57 of approximately 10,000 genes from purified myeloma cells could be used to distinguish the two groups of patients (P<0.001). Permutation analysis, which adjusts the significance level to account for multiple comparisons in the data sets, showed that 4 of these 57 genes were significantly overexpressed by plasma cells from patients with focal lesions. One of these genes, dickkopf 1 (DKK1), and its corresponding protein (DKK1) were studied in detail because DKK1 is a secreted factor that has been linked to the function of osteoblasts. Immunohistochemical analysis of bone marrow–biopsy specimens showed that only myeloma cells contained detectable DKK1. Elevated DKK1 levels in bone marrow plasma and peripheral blood from patients with multiple myeloma correlated with the gene-expression patterns of DKK1 and were associated with the presence of focal bone lesions. Recombinant human DKK1 or bone marrow serum containing an elevated level of DKK1 inhibited the differentiation of osteoblast precursor cells in vitro.
Conclusions
The production of DKK1, an inhibitor of osteoblast differentiation, by myeloma cells is associated with the presence of lytic bone lesions in patients with multiple myeloma.
Media in This Article
Figure 1
Differences in Global Patterns of Gene Expression between 137 Patients with Myeloma and One or More Bone Lesions on MRI and 36 Patients with Myeloma without Bone Lesions on MRI (Panel A) and DKK1 Gene Expression in Plasma Cells from 45 Control Subjects with Normal Bone Marrow, 16 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), 9 with Waldenström's Macroglobulinemia (WM), and the 173 with Multiple Myeloma (Panel B).Figure 2
Overexpression of DKK1 in Low-Grade Myeloma, with the Loss of Expression with Disease Progression.Article Activity
- Article
Lung, breast, and prostate cancer and multiple myeloma have an affinity for bone, where they cause osteoblastic lesions (prostate cancer) or osteolytic lesions (lung and breast cancer and multiple myeloma).1 Research on the mechanisms by which multiple myeloma cells induce osteolysis has focused on the osteoclast's role in shifting the normal balance between bone formation and bone resorption in favor of resorption.2 Bone resorption is blocked by bisphosphonates,3 but the inability of these compounds to repair lytic lesions indicates that a functional defect of osteoblasts is also important in the lytic process. Indeed, the number and function of osteoblasts are decreased in myeloma with osteolytic lesions.4-7
The Wnt signaling pathway is important for the growth and differentiation of osteoblasts and acts in several developmental processes.8 Disabling mutations in the gene for the Wnt coreceptor low-density lipoprotein receptor–related protein 5 (LRP5) cause the osteoporosis–pseudoglioma syndrome,9 and Lrp5-deficient mice have osteopenia with diminished osteoblast proliferation.10 In the syndrome of hereditary high bone density,11,12 mutations in the LRP5 gene prevent binding of dickkopf 1 (DKK1), a soluble inhibitor of Wnt, to LRP5.12-16 The importance of DKK1 in skeletal development has been further demonstrated by the extra digits in dkk1 null mice13 and by the loss of bony structures in chicken and mouse embryos after exposure to elevated levels of DKK1.13,14 In vitro, short-term exposure to low levels of DKK1 induces moderate proliferation of mesenchymal stem cells, whereas long-term exposure to high levels of DKK1 causes a loss of cell viability.15
In this study, we compared patterns of gene expression in myeloma cells, as has been done previously in the study of myeloma,16-18 to determine whether they were related to the presence or absence of bone lesions in myeloma.
Methods
Patients
We studied 173 patients with newly diagnosed multiple myeloma, 16 patients with monoclonal gammopathy of undetermined significance, 9 patients with Waldenström's macroglobulinemia, and 45 control subjects. The institutional review board of the University of Arkansas for Medical Sciences approved the research studies, and all subjects provided written informed consent. Table 1Table 1
Relation of the Characteristics of 173 Patients with Multiple Myeloma to the Presence or Absence of Bone Lesions on Magnetic Resonance Imaging (MRI). shows the characteristics of the patients with multiple myeloma.Bone Imaging
Images were reviewed by one of the investigators, who had no prior knowledge of the gene-expression data, using a Canon Picture Archiving and Cataloging System. Magnetic resonance imaging (MRI) scans were performed on 1.5-Tesla Signa scanners (General Electric). The radiographs were digitized from film in accordance with American College of Radiology standards. MRI scans and radiographs were transferred to the Canon Picture Archiving and Cataloging System with the use of the American College of Radiology's Digital Imaging and Communications in Medicine standard. Imaging was performed in accordance with the manufacturers' specifications. MRI images were created with T1-weighting both before and after the administration of gadolinium, with fat suppression, and with short-tau inversion recovery (STIR) weighting.
Plasma-Cell Isolation and Gene-Expression Profiling
After Ficoll–Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear-cell fraction by immunomagnetic bead selection with the use of a monoclonal mouse antihuman CD138 antibody (Miltenyi-Biotec). More than 90 percent of the cells used for gene-expression profiling were plasma cells, as shown by two-color flow cytometry with the use of CD138+/CD45– and CD38+/CD45– markers, the presence of cytoplasmic immunoglobulin light chains on immunocytochemical analysis, and morphologic features as determined with the use of Wright–Giemsa staining. Total RNA was isolated with an RNeasy Mini Kit (Qiagen). Preparation of labeled complementary RNA and hybridization to U95Av2 microarrays containing approximately 10,000 genes (Affymetrix) were performed as previously described.16,17 RNA amplification was not required. The results of gene-expression profiling were deposited in Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE755.
Immunohistochemistry
An antibody from a goat that had been immunized against the entire human DKK1 protein (R&D Systems) was diluted 1:200 in TRIS buffer and added to formalin-fixed, paraffin-embedded bone marrow–biopsy sections, which were then incubated for two hours at room temperature. Adjacent sections were stained with hematoxylin and eosin. Antigen–antibody reactions were developed with diamino DAB (after staining with biotinylated antigoat antibody [Vector Laboratories], at 1:400 dilution, and streptavidin–horseradish peroxidase [Dako]) and counterstained with hematoxylin-2.
Enzyme-Linked Immunosorbent Assay
Microtiter plates (Nunc-Immuno MaxiSorp surface) were coated with 50 μl of anti-DKK1 antibody at a concentration of 1 μg per milliliter in phosphate-buffered saline, pH 7.2, and incubated at 4°C overnight, and the reaction was blocked with 4 percent bovine serum albumin. Bone marrow plasma was diluted 1:50 in dilution buffer (1× phosphate-buffered saline plus 0.1 percent Tween-20 and 1 percent bovine serum albumin). A total of 50 μl was loaded per well and incubated overnight at 4°C, washed, and incubated with biotinylated goat antihuman DKK1 IgG (R&D Systems) diluted to a concentration of 0.2 μg per milliliter in dilution buffer, followed by the addition of 50 μl of a 1:10,000 dilution of streptavidin–horseradish peroxidase (Vector Laboratories), all according to the manufacturers' recommendations. Color development was achieved with the OPD substrate system (Dako), used according to the manufacturer's instructions. Serial dilutions of recombinant human DKK1 (R&D Systems) were used to establish a standard curve. The cell line T293, which does not express endogenous DKK1, and T293 with stably transfected DKK119 were used to validate the enzyme-linked immunosorbent assay.
Osteoblast-Differentiation Assays
C2C12 mesenchymal precursor cells (American Type Tissue Culture) were cultured in Dulbecco's minimal essential medium (Invitrogen) supplemented with 10 percent heat-inactivated fetal-calf serum. Alkaline phosphatase activity in C2C12 cells was measured as described previously.20,21 Cell lysates were analyzed for protein content with the use of the micro-BCA assay kit (Pierce). Each experiment was done in triplicate.
Statistical Analysis
Logistic regression was used to model bone disease in multiple myeloma. The independent variables considered were gene-expression intensity values (referred to as signals) from approximately 10,000 genes (12,625 probe sets), measured with the use of MAS software, version 5.01 (Affymetrix), from 173 patients with newly diagnosed multiple myeloma. The signal, a quantitative measure of gene expression, for each probe set was log transformed on a base-2 scale before it was entered into the logistic-regression model and subjected to permutation analysis, which adjusts the significance level to account for multiple comparisons in data sets with high dimensionality.
There was no prior hypothesis with regard to genes that might be associated with bone disease in myeloma. As a result, we used a univariate model of bone disease for each of the 12,625 probe sets. Candidate genes were refined with the use of t-tests with permutation-adjusted significance levels.22 Westfall and Young analysis was used to adjust for the multiple univariate-hypothesis tests. Group differences in DKK1 signal and DKK1 protein levels were tested with the use of the Wilcoxon rank-sum test.
Significant differences in patients' characteristics according to their bone-disease status were evaluated with the use of either Fisher's exact test or the chi-square test. The expression intensities of genes identified by logistic regression were classified with the use of Clusterview.23 Spearman's correlation coefficient was used to measure the correlation between the level of gene expression and protein levels. Significant differences in osteoblast differentiation between the control and each experimental condition were tested with the use of the Wilcoxon rank-sum test; separate comparisons were made for each unique C2C12 experiment. Two-sided P values of less than 0.05 were considered to indicate statistical significance, and two-sided P values of less than 0.10 were considered to indicate marginal statistical significance.
Results
Gene-Expression Profiling of Myeloma Cells
We sought to identify genes that were overexpressed and associated with the presence of bone lesions in patients with myeloma by comparing microarray data for patients who had bone lesions with data for those who did not have bone lesions. Since focal lesions of bone can be seen on MRI before lytic lesions can be identified radiologically, we used T1-weighted and STIR-weighted imaging to detect bone lesions. The patterns of expression of approximately 10,000 genes in purified plasma cells from the marrow of 36 patients with no detectable bone lesions and 137 with one or more focal lesions on MRI were modeled by logistic-regression analysis. The model identified 57 genes that were expressed differently (P<0.001) in the two groups of patients (Figure 1AFigure 1
Differences in Global Patterns of Gene Expression between 137 Patients with Myeloma and One or More Bone Lesions on MRI and 36 Patients with Myeloma without Bone Lesions on MRI (Panel A) and DKK1 Gene Expression in Plasma Cells from 45 Control Subjects with Normal Bone Marrow, 16 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), 9 with Waldenström's Macroglobulinemia (WM), and the 173 with Multiple Myeloma (Panel B).).These 57 genes were further analyzed by t-tests after adjustment for permutation.22 These statistical tests showed that 4 of the 57 genes were overexpressed in patients with one or more lesions on MRI: the genes for dihydrofolate reductase (DHFR), proteasome activator subunit (PSME2), CDC28 protein kinase 2 (CKS2), and DKK1. Given that the gene for the Wnt-signaling antagonist DKK1 is the only one of the four that codes for a secreted factor and that Wnt signaling is implicated in bone formation, we carried out further tests on DKK1.
An analysis of the results from the 173 patients with myeloma showed that the DKK1 plasma-cell signal for patients who had one or more lesions on MRI and no radiographic evidence of lesions differed significantly from the signal for patients who had no lesions detectable on MRI or radiography (the median signals were 2220 and 285, respectively; P<0.001) (Table 2Table 2
Levels of Expression of the DKK1 Gene and DKK1 Protein in Patients with Multiple Myeloma, According to the Presence or Absence of Bone Lesions on MRI and Radiography.). The DKK1 plasma-cell signals for patients who had one or more lesions on MRI and no radiographic evidence of lesions did not differ significantly from those for patients with one or more lesions on MRI and radiography (the median signals were 2220 and 1865, respectively; P=0.63) (Figure 1B and Table 2).Monoclonal gammopathy of undetermined significance is a plasma-cell dyscrasia that does not cause lytic bone lesions and that can precede multiple myeloma. In 15 of 16 patients with monoclonal gammopathy of undetermined significance, DKK1 was expressed by bone marrow plasma cells at levels similar to those in patients with multiple myeloma who had no lesions of bone on MRI or radiology (Figure 1B). DKK1 was essentially undetectable in plasma cells from 45 control subjects and 9 patients with Waldenström's macroglobulinemia, a plasma-cell cancer of the bone that does not cause bone lesions (Figure 1B).
Synthesis of DKK1 by Plasma Cells
Serial sections of bone marrow–biopsy specimens from 65 patients with multiple myeloma were stained for the presence of DKK1 (Figure 2Figure 2
Overexpression of DKK1 in Low-Grade Myeloma, with the Loss of Expression with Disease Progression.). The levels of DKK1 in plasma cells from these patients were consistent with the level of expression of DKK1 (data not shown). Similar experiments with biopsy specimens from five control subjects failed to identify DKK1 in any cell. Forty-two of 45 DKK1-positive myelomas had low-grade morphologic findings (abundant cytoplasm without apparent nucleoli) with an interstitial pattern of growth; staining was greatest in plasma cells adjacent to bone. Nineteen of 20 DKK1-negative myelomas had high-grade, plasmablastic morphologic findings (enlarged nuclei and prominent nucleoli) with a nodular or obliterative pattern of growth. In biopsy specimens with an interstitial pattern of growth, DKK1 was either present in various percentages of cells or absent. In contrast, DKK1 was uniformly absent from myelomas with the more aggressive nodular growth pattern. In the three patients with both interstitial and nodular growth, the interstitial cells were positive for DKK1, and the nodular cells were negative.DKK1 in Bone Marrow Plasma
An enzyme-linked immunosorbent assay showed that the mean (±SD) level of DKK1 protein in the bone marrow plasma from 107 of the 173 patients with newly diagnosed multiple myeloma for whom gene-expression data were also available was 24.0±49.6 ng per milliliter. In contrast, the DKK1 level was 8.9±4.2 ng per milliliter in bone marrow plasma from 14 control subjects, 7.5±4.5 ng per milliliter in 14 patients with monoclonal gammopathy of undetermined significance, and 5.5±2.4 ng per milliliter in 9 patients with Waldenström's macroglobulinemia. The level of DKK1 expression and the level of DKK1 in bone marrow plasma were positively correlated (r=0.65, P<0.001) in the 107 patients with myeloma (Figure 3AFigure 3
Correlation between Levels of DKK1 in Bone Marrow Plasma and Level of DKK1 Expression in Plasma Cells (Panel A) and Correlation of Levels of DKK1 in Bone Marrow Plasma and the Presence or Absence of Bone Lesions (Panel B).). There was also a strong correlation between DKK1 protein levels in bone marrow plasma and peripheral-blood plasma in 41 patients with myeloma from whom both samples were obtained simultaneously (r=0.57, P<0.001). In 68 patients in whom both DKK1 levels in the bone marrow plasma and the presence of bone lesions were determined, DKK1 levels in patients with one or more lesions on MRI and no radiographic evidence of lesions differed significantly from those in patients with no lesions on MRI or radiography (median level, 20 ng per milliliter and 9 ng per milliliter, respectively; P=0.002), but not from those in patients with one or more lesions on both MRI and radiography (median level, 14 ng per milliliter; P=0.36) (Figure 3B and Table 2).Effect of Bone Marrow Plasma on Osteoblast Differentiation in Vitro
Bone morphogenetic protein type 2 (BMP-2) can induce differentiation of the uncommitted mesenchymal progenitor-cell line C2C1224 into osteoblasts through a mechanism that involves Wnt/β-catenin signaling.25,26 Only small amounts of alkaline phosphatase, a specific marker of osteoblast differentiation, were detectable in C2C12 cells grown in 5 percent fetal-calf serum for five days (Figure 4AFigure 4
Effect of Recombinant DKK1 (rhDKK1) and Bone Marrow Plasma from Patients with Multiple Myeloma on Alkaline Phosphatase Production in C2C12 Cells Treated with Bone Morphogenetic Protein Type 2 (BMP-2).). Treatment of C2C12 cells with 50 ng of BMP-2 per milliliter for five days induced them to produce alkaline phosphatase, whereas alkaline phosphatase was inhibited in C2C12 cells that were concomitantly cultured with BMP-2 and 50 ng of recombinant human DKK1 per milliliter. This in vitro effect on alkaline phosphatase production was neutralized by a polyclonal anti-DKK1 antibody but not by a nonspecific polyclonal goat IgG. Bone marrow plasma with a DKK1 level of more than 12 ng per milliliter, obtained from five patients with myeloma, inhibited the production of alkaline phosphatase by C2C12 cells treated with BMP-2, and this effect was reversed by the anti-DKK1 antibody but not by nonspecific IgG (Figure 4B). By contrast, C2C12 cells treated with 50 ng of BMP-2 per milliliter and 10 percent plasma from the bone marrow of a control subject induced the production of alkaline phosphatase by the cells (Figure 4B).Discussion
Using oligonucleotide microarrays, we examined the expression of approximately 10,000 genes by purified plasma cells from the marrow of 137 patients with and 36 without detectable bone lesions at the time of diagnosis of multiple myeloma. After logistic-regression analysis and permutation adjustment, we found significant overexpression of four genes by plasma cells from patients with bone lesions. Only one of these four, DKK1, codes for a secreted protein with a demonstrated role in bone formation. We also detected DKK1 protein in myeloma cells from patients with bone lesions but not in normal plasma cells or in plasma cells from patients who had myeloma without bone lesions, and we found that marrow plasma and blood plasma from patients with myeloma and bone lesions contained higher amounts of the protein. Moreover, an elevated level of DKK1 was associated not only with the presence of bone lesions, but also with increased levels of DKK1 transcripts in myeloma cells. We also demonstrated that plasma from the marrow of some patients with myeloma can block osteoblast differentiation in vitro and that this effect was neutralized by an anti-DKK1 antibody.
The function of osteoblasts is dramatically reduced when the proportion of myeloma cells in the marrow exceeds 50 percent,5,7,27,28 a finding that suggests a link between elevated DKK1 levels in the circulating blood and the diffuse osteopenia that can occur in multiple myeloma. Recent in vitro studies have shown that short-term exposure of mesenchymal stem cells (osteoblast precursors) to low levels of recombinant DKK1 caused them to proliferate, whereas long-term exposure to high levels caused a loss of viability.15 Thus, in addition to blocking the terminal differentiation of osteoblasts, the sustained high levels of DKK1 in the bone marrow of patients with multiple myeloma may also cause a loss in viability of osteoblast stem cells.
Immunosuppression and anemia represent serious complications in patients with multiple myeloma and are thought to be caused by a cancer-related defect in hematopoiesis. Given that hematopoietic stem-cell proliferation is dependent on a bone marrow niche that is created by osteoblasts29,30 and that canonical Wnt signals can directly regulate the capacity of hematopoietic stem cells for self-renewal,31,32 elevated levels of DKK1 may also have a role in causing immunosuppression and anemia. We hypothesize that DKK1 could block proliferation of hematopoietic stem cells directly by blocking canonical Wnt signaling on such cells or indirectly by inhibition of osteoblast differentiation — hence the establishment of the bone marrow microenvironmental niche that hematopoietic stem cells require for proliferation. Elevated levels of DKK1 may also negatively influence several important steps in the mobilization, engraftment, and proliferation of hematopoietic stem cells during the course of autologous transplantation, which is now considered the therapy of choice in the treatment of multiple myeloma.33
Not all patients with newly diagnosed multiple myeloma who had lytic bone lesions had elevated levels of expression of the DKK1 gene or protein. DKK1 is rarely detected in plasma cells from patients with monoclonal gammopathy of undetermined significance or patients with myeloma who have end-stage disease or secondary plasma-cell leukemia (unpublished data), indicating that increased DKK1 expression is restricted to a specific stage of the disease.
An interaction between the receptor activator of nuclear factor-κB (RANK) ligand and RANK, or osteoprotegerin, has a dominant role in the activation and survival of osteoclasts,34,35 and elevated serum levels of RANK ligand are associated with markers of bone resorption, osteolytic lesions, and reduced survival in multiple myeloma.36-38 Moreover, immature, but not mature, osteoblasts are rich sources of RANK ligand.39 For these reasons, it is plausible that the DKK1-mediated block in osteoblast differentiation may stimulate osteoclasts, because osteoblast precursors produce relatively large amounts of RANK ligand. We have recently shown that in vitro coculture of DKK1-positive myeloma cells with osteoclasts results in significant down-regulation of the expression of DKK1 in plasma cells.40 Thus, the findings in the subgroup of patients who have myeloma with lytic lesions who do not express DKK1 may be representative of more advanced disease, in which the down-regulation of DKK1 is mediated by an increase in the numbers of osteoclasts.
We propose that the DKK1 produced by myeloma cells blocks the differentiation of osteoblasts and promotes the early proliferation and, subsequently, the reduced viability of mesenchymal stem cells. During progression of the disease, these events would shift the balance between osteoblasts and osteoclasts in favor of osteoclasts, thereby diminishing bone formation and enhancing bone resorption and, hence, the development of lytic lesions.
Supported by private funding from the Fund to Cure Myeloma and the Penninsula Community Foundation (to Dr. Shaughnessy) and by grants (CA55819, to Drs. Barlogie and Shaughnessy; and CA97513, to Dr. Shaughnessy) from the National Cancer Institute.
Mr. Tian and Dr. Zhan contributed equally to the article.
We are indebted to members of the Lambert Laboratory — Wade Gregory, Yongsheng Huang, Bob Kordsmeier, Kelly McCastlain, Chris Randolph, Madhumita Santra, Ruston Smith, Owen Stephens, Yan Xaio, and Hong Wei Xu — and to Li Han of the Manolagas Laboratory for excellent technical assistance; to Drs. Joshua Epstein, Larry Suva, Stavroula Kousteni, Stavros Manolagas, Andrew Zannettino, and Peter Croucher for helpful discussions; to Dr. Stuart Aaronson for providing the T293 cell lines; to the clinicians of the Myeloma Institute for Research and Therapy for referring patients to this study; and to all the patients who have helped us in our pursuit of a cure for this dreaded disease.
Source Information
From the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy (E.T., F.Z., B.B., J.D.S.), and the Departments of Radiology (R.W.) and Pathology (Y.M.), College of Medicine, University of Arkansas for Medical Sciences, Little Rock; and Cancer Research and Biostatistics, Seattle (E.R.).
Address reprint requests to Dr. Shaughnessy at the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, or at jshaughnessy@uams.edu.
- References
References
1
Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593
CrossRef | Web of Science | Medline2
Roodman GD . Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-3571
Web of Science | Medline3
Berenson JR ,Lichtenstein A ,Porter L , et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-493
Full Text | Web of Science | Medline4
Bataille R ,Chappard D ,Alexandre C ,Dessauw P ,Sany J . Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986;53:805-810
CrossRef | Web of Science | Medline5
Bataille R ,Chappard D ,Marcelli C , et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88:62-66
CrossRef | Web of Science | Medline6
Bataille R ,Chappard D ,Marcelli C , et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 1990;76:484-487
CrossRef | Web of Science | Medline7
Taube T ,Beneton MN ,McCloskey EV ,Rogers S ,Greaves M ,Kanis JA . Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-198
CrossRef | Web of Science | Medline8
Cadigan KM ,Nusse R . Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305
CrossRef | Web of Science | Medline9
Gong Y ,Slee RB ,Fukai N , et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-523
CrossRef | Web of Science | Medline10
Kato M ,Patel MS ,Levasseur R , et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002;157:303-314
CrossRef | Web of Science | Medline11
Little RD ,Carulli JP ,Del Mastro RG , et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19
CrossRef | Web of Science | Medline12
Boyden LM ,Mao J ,Belsky J , et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-1521
Full Text | Web of Science | Medline13
Mukhopadhyay M ,Shtrom S ,Rodriguez-Esteban C , et al. Dickkopf 1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001;1:423-434
CrossRef | Web of Science | Medline14
Grotewold L ,Ruther U . The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 2002;21:966-975
CrossRef | Web of Science | Medline15
Gregory CA ,Singh H ,Perry AS ,Prockop DJ . The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003;278:28067-28078
CrossRef | Web of Science | Medline16
Zhan F ,Hardin J ,Kordsmeier B , et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-1757
CrossRef | Web of Science | Medline17
Zhan F ,Tian E ,Bumm K ,Smith R ,Barlogie B ,Shaughnessy J Jr . Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003;101:1128-1140
CrossRef | Web of Science | Medline18
Shaughnessy J ,Jacobson J ,Sawyer J , et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003;101:3849-3856
CrossRef | Web of Science | Medline19
Fedi P ,Bafico A ,Nieto Soria A , et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999;274:19465-19472
CrossRef | Web of Science | Medline20
Gallea S ,Lallemand F ,Atfi A , et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001;28:491-498
CrossRef | Web of Science | Medline21
Spinella-Jaegle S ,Roman-Roman S ,Faucheu C , et al. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. Bone 2001;29:323-330
CrossRef | Web of Science | Medline22
Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: Wiley-Interscience, 1993:360.
23
Golub TR ,Slonim DK ,Tamayo P , et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537
CrossRef | Web of Science | Medline24
Katagiri T ,Yamaguchi A ,Komaki M , et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994;127:1755-1766[Erratum, J Cell Biol 1995;128:713a.]
CrossRef | Web of Science | Medline25
Bain G ,Muller T ,Wang X ,Papkoff J . Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003;301:84-91
CrossRef | Web of Science | Medline26
Rawadi G ,Vayssiere B ,Dunn F ,Baron R ,Roman-Roman S . BMP-2 controls alkaline phosphate expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003;18:1842-1853
CrossRef | Web of Science | Medline27
Valentin-Opran A ,Charhon SA ,Meunier PJ ,Edouard CM ,Arlot ME . Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982;52:601-610
CrossRef | Web of Science | Medline28
Roux C ,Ravaud P ,Cohen-Solal M , et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-49
CrossRef | Web of Science | Medline29
Zhang J ,Niu C ,Ye L , et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836-841
CrossRef | Web of Science | Medline30
Calvi LM ,Adams GB ,Weibrecht KW , et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-846
CrossRef | Web of Science | Medline31
Reya T ,Duncan AW ,Ailles L , et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-414
CrossRef | Web of Science | Medline32
Murdoch B ,Chadwick K ,Martin M , et al. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc Natl Acad Sci U S A 2003;100:3422-3427
CrossRef | Web of Science | Medline33
Barlogie B, Shaughnessy JD, Tricot G, et al. Treatment of multiple myeloma. Blood (in press).
34
Lacey DL ,Timms E ,Tan HL , et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176
CrossRef | Web of Science | Medline35
Suda T ,Takahashi N ,Udagawa N ,Jimi E ,Gillespie MT ,Martin TJ . Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357
CrossRef | Web of Science | Medline36
Pearse RN ,Sordillo EM ,Yaccoby S , et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98:11581-11586
CrossRef | Web of Science | Medline37
Sezer O ,Heider U ,Zavrski I ,Kuhne CA ,Hofbauer LC . RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098
CrossRef | Web of Science | Medline38
Terpos E ,Szydlo R ,Apperley JF , et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-1069
CrossRef | Web of Science | Medline39
Atkins GJ ,Kostakis P ,Pan B , et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003;18:1088-1098
CrossRef | Web of Science | Medline40
Yaccoby S ,Zhan F ,Xu HW ,Barlogie B ,Epstein J ,Shaughnessy J . Significant and consistent gene expression changes highlight the molecular consequences of myeloma and normal donor plasma cell interactions with osteoclasts. Blood 2002;100:607a-607a abstract.
CrossRef | Web of Science
- Citing Articles (357)
Citing Articles
1
Ayako Nakano, Hirokazu Miki, Shingen Nakamura, Takeshi Harada, Asuka Oda, Hiroe Amou, Shiro Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto, Masahiro Abe. (2012) Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. Journal of Bioenergetics and Biomembranes
CrossRef2
N Giuliani, M Ferretti, M Bolzoni, P Storti, M Lazzaretti, B Dalla Palma, S Bonomini, E Martella, L Agnelli, A Neri, F Ceccarelli, C Palumbo. (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia
CrossRef3
Jürgen Veeck, Edgar Dahl. (2012) Targeting the Wnt pathway in cancer: The emerging role of Dickkopf-3. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1825:1, 18-28
CrossRef4
Maurizio Zangari, Evangelos Terpos, Fenghuang Zhan, Guido Tricot. (2012) Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treatment Reviews
CrossRef5
Wei Zhang, Matthew T. Drake. (2011) Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the Treatment of Osteoporosis. Current Osteoporosis Reports
CrossRef6
Sonia Vallet, Noopur Raje. (2011) Bone Anabolic Agents for the Treatment of Multiple Myeloma. Cancer Microenvironment
CrossRef7
Jong-Min Lee, Seita Miyazawa, Jeong-Oh Shin, Hyuk-Jae Kwon, Dae-Woon Kang, Byung-Jai Choi, Jae-Ho Lee, Shigeru Kondo, Sung-Won Cho, Han-Sung Jung. (2011) Shh signaling is essential for rugae morphogenesis in mice. Histochemistry and Cell Biology 136:6, 663-675
CrossRef8
J. Qian, Y. Zheng, C. Zheng, L. Wang, H. Qin, S. Hong, H. Li, Y. Lu, J. He, J. Yang, S. Neelapu, L. W. Kwak, J. Hou, Q. Yi. (2011) Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood
CrossRef9
Xiaodong Li, Mario Grisanti, Wei Fan, Frank J Asuncion, Hong-Lin Tan, Denise Dwyer, Chun-Ya Han, Longchuan Yu, Jae Lee, Edward Lee, Mauricio Barrero, Pam Kurimoto, Qing-Tian Niu, Zhaopo Geng, Aaron Winters, Tom Horan, Shirley Steavenson, Frederick Jacobsen, Qing Chen, Raj Haldankar, Jennifer Lavallee, Barbara Tipton, Mark Daris, Jackie Sheng, Hsieng S Lu, Kristi Daris, Rohini Deshpande, Eliane G Valente, Hossein Salimi-Moosavi, Paul J Kostenuik, Ji Li, Min Liu, Chaoyang Li, David L Lacey, W Scott Simonet, Hua Zhu Ke, Philip Babij, Marina Stolina, Michael S Ominsky, William G Richards. (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. Journal of Bone and Mineral Research 26:11, 2610-2621
CrossRef10
Sung H. Kim, Stacy E. Smith, Michael E. Mulligan. (2011) Hematopoietic Tumors and Metastases Involving Bone. Radiologic Clinics of North America 49:6, 1163-1183
CrossRef11
Mitsuru Haniu, Tom Horan, Chris Spahr, John Hui, Wei Fan, Ching Chen, William G. Richards, Hsieng S. Lu. (2011) Human Dickkopf-1 (huDKK1) protein: Characterization of glycosylation and determination of disulfide linkages in the two cysteine-rich domains. Protein Science 20:11, 1802-1813
CrossRef12
David G. Monroe, Meghan E. McGee-Lawrence, Merry Jo Oursler, Jennifer J. Westendorf. (2011) Update on Wnt signaling in bone cell biology and bone disease. Gene
CrossRef13
Xiaosheng Wang. (2011) Robust two-gene classifiers for cancer prediction. Genomics
CrossRef14
A. C. Ng, S. Khosla, N. Charatcharoenwitthaya, S. K. Kumar, S. J. Achenbach, M. F. Holets, L. K. McCready, L. J. Melton, R. A. Kyle, S. V. Rajkumar, M. T. Drake. (2011) Bone microstructural changes revealed by HRpQCT imaging and elevated DKK1 and MIP-1 levels in patients with monoclonal gammopathy of undetermined significance. Blood
CrossRef15
S. D'Souza, D. Del Prete, S. Jin, Q. Sun, A. J. Huston, F. E. Kostov, B. Sammut, C.-S. Hong, J. L. Anderson, K. D. Patrene, S. Yu, C. S. Velu, G. Xiao, H. L. Grimes, G. D. Roodman, D. L. Galson. (2011) Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood
CrossRef16
Séverine Lecourt, Valérie Vanneaux, Audrey Cras, Delphine Freida, Djazia Heraoui, Linda Herbi, Catherine Caillaud, Christine Chomienne, Jean-Pierre Marolleau, Nadia Belmatoug, Jérôme Larghero. (2011) Bone Marrow Microenvironment in an In Vitro Model of Gaucher Disease: Consequences of Glucocerebrosidase Deficiency. Stem Cells and Development111018073428009
CrossRef17
Teru Hideshima, Kenneth C. Anderson. (2011) Novel therapies in MM: from the aspect of preclinical studies. International Journal of Hematology 94:4, 344-354
CrossRef18
Dimitrios Daoussis, Andrew P. Andonopoulos. (2011) The Emerging Role of Dickkopf-1 in Bone Biology: Is It the Main Switch Controlling Bone and Joint Remodeling?. Seminars in Arthritis and Rheumatism 41:2, 170-177
CrossRef19
Masahiro Abe. (2011) Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. International Journal of Hematology 94:4, 334-343
CrossRef20
Sarah K. Johnson, Christoph J. Heuck, Anthony P. Albino, Pingping Qu, Qing Zhang, Bart Barlogie, John D. Shaughnessy. (2011) The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. International Journal of Hematology 94:4, 321-333
CrossRef21
Nilay Sethi, Yibin Kang. (2011) Unravelling the complexity of metastasis — molecular understanding and targeted therapies. Nature Reviews Cancer 11:10, 735-748
CrossRef22
Fernando Lecanda. (2011) Tumor–stroma: role of the tumor microenvironment during bone metastasis: unveiling therapeutic targets. Drug Discovery Today: Disease Models 8:2-3, 87-93
CrossRef23
Flaminia Coluzzi, Ilenia Mandatori, Consalvo Mattia. (2011) Emerging therapies in metastatic bone pain. Expert Opinion on Emerging Drugs 16:3, 441-458
CrossRef24
N W C J van de Donk, S Kamps, T Mutis, H M Lokhorst. (2011) Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia
CrossRef25
Ping Wu, Gareth J. Morgan. (2011) Targeting Bone as a Therapy for Myeloma. Cancer Microenvironment
CrossRef26
Jin Zhang, Qisheng Tu, Lynda F Bonewald, Xi He, Gary Stein, Jane Lian, Jake Chen. (2011) Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. Journal of Bone and Mineral Research 26:8, 1953-1963
CrossRef27
Seong-Ryul Kwon, Mie-Jin Lim, Chang-Hee Suh, Shin-Goo Park, Yeon-Sik Hong, Bo-Young Yoon, Hyoun-Ah Kim, Hyo-Jin Choi, Won Park. (2011) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatology International
CrossRef28
Dallas Jones, Laurie H. Glimcher, Antonios O. Aliprantis. (2011) Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. Journal of Clinical Investigation 121:7, 2534-2542
CrossRef29
Dan Zhou, Yukun Zhang, Yuan-Xiang Pan, Hong Chen. (2011) Dickkopf homolog 1, a Wnt signaling antagonist, is transcriptionally up-regulated via an ATF4-independent and MAPK/ERK-dependent pathway following amino acid deprivation. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1809:7, 306-315
CrossRef30
Jesús M. Hernández, Isabel Granada, Francesc Solé. (2011) De la citogenética convencional al análisis por micromatrices. Cincuenta años del cromosoma Filadelfia. Medicina Clínica 137:5, 221-229
CrossRef31
S Vallet, S Pozzi, K Patel, N Vaghela, M T Fulciniti, P Veiby, T Hideshima, L Santo, D Cirstea, D T Scadden, K C Anderson, N Raje. (2011) A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 25:7, 1174-1181
CrossRef32
Julie C Baker-LePain, Mary C Nakamura, Nancy E Lane. (2011) Effects of inflammation on bone: an update. Current Opinion in Rheumatology 23:4, 389-395
CrossRef33
Sigurdur Y Kristinsson, Alex R Minter, Neha Korde, Esther Tan, Ola Landgren. (2011) Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Review of Molecular Diagnostics 11:6, 593-603
CrossRef34
Maurizio Zangari, Monette Aujay, Fenghuang Zhan, Kristina L. Hetherington, Tamara Berno, Ravi Vij, Sundar Jagannath, David Siegel, A. Keith Stewart, Luhua Wang, Robert Z. Orlowski, Andrew Belch, Andrzej Jakubowiak, George Somlo, Suzanne Trudel, Nizar Bahlis, Sagar Lonial, Seema Singhal, Vishal Kukreti, Guido Tricot. (2011) Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. European Journal of Haematology 86:6, 484-487
CrossRef35
Sylvia Thiele, Martina Rauner, Claudia Goettsch, Tilman D. Rachner, Peggy Benad, Susanne Fuessel, Kati Erdmann, Christine Hamann, Gustavo B. Baretton, Manfred P. Wirth, Franz Jakob, Lorenz C. Hofbauer. (2011) Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. Journal of Cellular Biochemistry 112:6, 1593-1600
CrossRef36
S Colucci, G Brunetti, A Oranger, G Mori, F Sardone, G Specchia, E Rinaldi, P Curci, V Liso, G Passeri, A Zallone, R Rizzi, M Grano. (2011) Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal 1:6, e27
CrossRef37
Katherine N. Weilbaecher, Theresa A. Guise, Laurie K. McCauley. (2011) Cancer to bone: a fatal attraction. Nature Reviews Cancer 11:6, 411-425
CrossRef38
Iago Porto-Díaz, Verónica Bolón-Canedo, Amparo Alonso-Betanzos, Oscar Fontenla-Romero. (2011) A study of performance on microarray data sets for a classifier based on information theoretic learning. Neural Networks
CrossRef39
D. Cejka, A. Jager-Lansky, H. Kieweg, M. Weber, C. Bieglmayer, D. G. Haider, D. Diarra, J. Patsch, F. Kainberger, B. Bohle, M. Haas. (2011) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrology Dialysis Transplantation
CrossRef40
Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel. (2011) Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology 86:5, 372-384
CrossRef41
S. Vincent Rajkumar. (2011) Treatment of multiple myeloma. Nature Reviews Clinical Oncology 8:8, 479-491
CrossRef42
Maripat Corr. 2011. WNT/_-Catenin Signaling Modulating Osteoarthritis. , 91-101.
CrossRef43
M Santra, JD Shaughnessy, WT Bellamy. (2011) Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique. Biotechnic & Histochemistry 86:2, 119-123
CrossRef44
Larry J. Suva, Charity Washam, Richard W. Nicholas, Robert J. Griffin. (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nature Reviews Endocrinology 7:4, 208-218
CrossRef45
Berit Grandaunet, Silje W. Syversen, Mari Hoff, Anders Sundan, Glenn Haugeberg, Desirée van Der Heijde, Tore K. Kvien, Therese Standal. (2011) Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis & Rheumatism 63:3, 662-669
CrossRef46
Joseph S. Butler, David W. Murray, Conor J. Hurson, Julie O'Brien, Peter P. Doran, John M. O'Byrne. (2011) The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density. Journal of Orthopaedic Research 29:3, 414-418
CrossRef47
Nobuhiro Kamiya, Yuji Mishina. (2011) New insights on the roles of BMP signaling in bone-A review of recent mouse genetic studies. BioFactors 37:2, 75-82
CrossRef48
Gang-Qing Yao, Jian-Jun Wu, Nancy Troiano, Karl Insogna. (2011) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. Journal of Bone and Mineral Metabolism 29:2, 141-148
CrossRef49
Kenneth C. Anderson, Ruben D. Carrasco. (2011) Pathogenesis of Myeloma. Annual Review of Pathology: Mechanisms of Disease 6:1, 249-274
CrossRef50
W. G. Gunn, U. Krause, N. Lee, C. A. Gregory. (2011) Pharmaceutical inhibition of glycogen synthetase kinase-3 reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 117:5, 1641-1651
CrossRef51
Evangelos Terpos, Meletios A. Dimopoulos, James Berenson. (2011) Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical Reviews in Oncology/Hematology 77, S13-S23
CrossRef52
Xin Li, Wen Ling, Angela Pennisi, Yuping Wang, Sharmin Khan, Mohammad Heidaran, Ajai Pal, Xiaokui Zhang, Shuyang He, Andy Zeitlin, Stewart Abbot, Herbert Faleck, Robert Hariri, John D. Shaughnessy, Frits van Rhee, Bijay Nair, Bart Barlogie, Joshua Epstein, Shmuel Yaccoby. (2011) Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone. STEM CELLS 29:2, 263-273
CrossRef53
G. David Roodman. (2011) Osteoblast function in myeloma. Bone 48:1, 135-140
CrossRef54
Philippe Clézardin. (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Research 13:2, 207
CrossRef55
Liviu Feller, Beverley Kramer, Johan Lemmer. (2011) A short account of metastatic bone disease. Cancer Cell International 11:1, 24
CrossRef56
Toshio Matsumoto, Masahiro Abe. (2011) TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone 48:1, 129-134
CrossRef57
Eric R. Wagner, Gaurav Luther, Gaohui Zhu, Qing Luo, Qiong Shi, Stephanie H. Kim, Jian-Li Gao, Enyi Huang, Yanhong Gao, Ke Yang, Linyuan Wang, Chad Teven, Xiaoji Luo, Xing Liu, Mi Li, Ning Hu, Yuxi Su, Yang Bi, Bai-Cheng He, Ni Tang, Jinyong Luo, Liang Chen, Guowei Zuo, Richard Rames, Rex C. Haydon, Hue H. Luu, Tong-Chuan He. (2011) Defective Osteogenic Differentiation in the Development of Osteosarcoma. Sarcoma 2011, 1-12
CrossRef58
Yuanyuan Liang, Donna P. Ankerst, Norma S. Ketchum, Barbara Ercole, Girish Shah, John D. Shaughnessy, Robin J. Leach, Ian M. Thompson. (2011) Prospective Evaluation of Operating Characteristics of Prostate Cancer Detection Biomarkers. The Journal of Urology 185:1, 104-110
CrossRef59
Jessica A. Fowler, Claire M. Edwards, Peter I. Croucher. (2011) Tumor–host cell interactions in the bone disease of myeloma. Bone 48:1, 121-128
CrossRef60
Judith M. Runnels, Alicia L. Carlson, Costas Pitsillides, Brian Thompson, Juwell Wu, Joel A. Spencer, John M. J. Kohler, AbdelKareem Azab, Anne-Sophie Moreau, Scott J. Rodig, Andrew L. Kung, Kenneth C. Anderson, Irene M. Ghobrial, Charles P. Lin. (2011) Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. Journal of Biomedical Optics 16:1, 011006
CrossRef61
Paula Garland, Philip Gishen, Amin Rahemtulla. (2011) Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits—long-term efficacy outcomes. Annals of Hematology 90:1, 95-100
CrossRef62
Sung-Eun Lee, Chang-Ki Min, Seung-Ah Yahng, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park. (2011) Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma. European Journal of Haematology 86:1, 83-86
CrossRef63
Alex R. Minter, Haley Simpson, Brendan M. Weiss, Ola Landgren. (2011) Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities. Seminars in Hematology 48:1, 55-65
CrossRef64
Nilay Sethi, Yibin Kang. (2011) Dysregulation of developmental pathways in bone metastasis. Bone 48:1, 16-22
CrossRef65
Xiaosheng Wang, Richard Simon. (2011) Microarray-based cancer prediction using single genes. BMC Bioinformatics 12:1, 391
CrossRef66
Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, Cornelia Bratengeier, Maria Gkotzamanidou, Eurydiki Michalis, Sosana Delimpasi, Anastasia Pouli, John Meletis, Efstathios Kastritis, Konstantinos Zervas, Meletios A. Dimopoulos. (2011) Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction post-bortezomib monotherapy. International Journal of Cancern/a-n/a
CrossRef67
Mitchell E. Menezes, Daniel J. Devine, Lalita A. Shevde, Rajeev S. Samant. (2011) Dickkopf1: A tumor suppressor or metastasis promoter?. International Journal of Cancern/a-n/a
CrossRef68
José Manuel González-Sancho, María Jesús Larriba, Alberto Muñoz. 2011. Vitamin D and Wnt/β-Catenin Signaling. , 235-250.
CrossRef69
Aaron J. Weiss, Jameel Iqbal, Neeha Zaidi, Jeffrey I. Mechanick. (2010) The Skeletal Subsystem as an Integrative Physiology Paradigm. Current Osteoporosis Reports 8:4, 168-177
CrossRef70
Antoine Popelut, Scott M. Rooker, Philipp Leucht, Marie Medio, John B. Brunski, Jill A. Helms. (2010) The acceleration of implant osseointegration by liposomal Wnt3a. Biomaterials 31:35, 9173-9181
CrossRef71
Tsu-Yi Chao, Yi-Ying Wu, Anthony J. Janckila. (2010) Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clinica Chimica Acta 411:21-22, 1553-1564
CrossRef72
Bingzong Li, Jinxing Fu, Ping Chen, Wenzhuo Zhuang. (2010) Impairment in Immunomodulatory Function of Mesenchymal Stem Cells from Multiple Myeloma Patients. Archives of Medical Research 41:8, 623-633
CrossRef73
Mi-Hee Kwack, Ji-Sup Ahn, Moon-Kyu Kim, Jung-Chul Kim, Young-Kwan Sung. (2010) Preventable effect of L-threonate, an ascorbate metabolite, on androgen-driven balding via repression of dihydrotestosteroneinduced dickkopf-1 expression in human hair dermal papilla cells. BMB Reports 43:10, 688-692
CrossRef74
S. Y. Kristinsson, M. Tang, R. M. Pfeiffer, M. Bjorkholm, C. Blimark, U.-H. Mellqvist, A. Wahlin, I. Turesson, O. Landgren. (2010) Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 116:15, 2651-2655
CrossRef75
B. A. Walker, P. E. Leone, L. Chiecchio, N. J. Dickens, M. W. Jenner, K. D. Boyd, D. C. Johnson, D. Gonzalez, G. P. Dagrada, R. K. M. Protheroe, Z. J. Konn, D. M. Stockley, W. M. Gregory, F. E. Davies, F. M. Ross, G. J. Morgan. (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116:15, e56-e65
CrossRef76
A. Broyl, D. Hose, H. Lokhorst, Y. de Knegt, J. Peeters, A. Jauch, U. Bertsch, A. Buijs, M. Stevens-Kroef, H. B. Beverloo, E. Vellenga, S. Zweegman, M.-J. Kersten, B. van der Holt, L. el Jarari, G. Mulligan, H. Goldschmidt, M. van Duin, P. Sonneveld. (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116:14, 2543-2553
CrossRef77
Thomas Lund, Kent Søe, Niels Abildgaard, Patrick Garnero, Per T. Pedersen, Tina Ormstrup, Jean-Marie Delaissé, Torben Plesner. (2010) First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. European Journal of Haematology 85:4, 290-299
CrossRef78
E Terpos, M A Dimopoulos, O Sezer, D Roodman, N Abildgaard, R Vescio, P Tosi, R Garcia-Sanz, F Davies, A Chanan-Khan, A Palumbo, P Sonneveld, M T Drake, J-L Harousseau, K C Anderson, B G M Durie. (2010) The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 24:10, 1700-1712
CrossRef79
Yinghui Huang, Xiaoxue Qiu, Ji-Long Chen. (2010) Identification of cancer stem cells: from leukemia to solid cancers. Frontiers in Biology 5:5, 407-416
CrossRef80
Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette Vangsted, Anne Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth-Hansen, Ingerid Nesthus, Inger Marie S Dahl, Jan Westin, Johan Lanng Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost Andersen, Olle Linder, Finn Wisløff. (2010) Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Lancet Oncology 11:10, 973-982
CrossRef81
S. V. Rajkumar, R. A. Kyle, F. K. Buadi. (2010) Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clinic Proceedings 85:10, 945-948
CrossRef82
Maurizio Zangari, Fenghuang Zhan, Guido Tricot. (2010) Bone and paraproteinemias. Current Opinion in Supportive and Palliative Care 4:3, 195-199
CrossRef83
Gerhard Krönke, Stefan Uderhardt, Kyung-Ah Kim, Michael Stock, Carina Scholtysek, Mario M. Zaiss, Cordula Surmann-Schmitt, Julia Luther, Julia Katzenbeisser, Jean-Pierre David, Shahla Abdollahi-Roodsaz, Karolyn Tran, Jessica M. Bright, Minke E. Binnerts, Alfiya Akhmetshina, Christina Böhm, Jörg H. Distler, Leo A. B. Joosten, Georg Schett, Arie Abo. (2010) R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis & Rheumatism 62:8, 2303-2312
CrossRef84
Allan Lipton. (2010) New approaches to treating and preventing bone metastases. Current Opinion in Supportive and Palliative Care1
CrossRef85
Daniel Chappard, Hélène Libouban, Erick Legrand, Norbert Ifrah, Charles Masson, Michel Felix Baslé, Maurice Audran. (2010) Computed Microtomography of Bone Specimens for Rapid Analysis of Bone Changes Associated With Malignancy. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 293:7, 1125-1133
CrossRef86
Evangelos Terpos. (2010) Bortezomib down-regulates the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease. Leukemia Research 34:6, 700-701
CrossRef87
James R. Berenson. (2010) Therapeutic Options in the Management of Myeloma Bone Disease. Seminars in Oncology 37, S20-S29
CrossRef88
Natasha Case, Janet Rubin. (2010) β-Catenin-A supporting role in the skeleton. Journal of Cellular Biochemistry 110:3, 545-553
CrossRef89
Liliana Guedez, William G. Stetler-Stevenson. (2010) The prognostic value of TIMP-1 in multiple myeloma. Leukemia Research 34:5, 576-577
CrossRef90
G. David Roodman. (2010) Targeting the bone microenvironment in multiple myeloma. Journal of Bone and Mineral Metabolism 28:3, 244-250
CrossRef91
Thomas Lund, Niels Abildgaard, Thomas L. Andersen, Jean-Marie Delaisse, Torben Plesner. (2010) Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*. European Journal of Haematology 84:5, 412-420
CrossRef92
Arun Balakumaran, Pamela Gehron Robey, Neal Fedarko, Ola Landgren. (2010) Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Review of Molecular Diagnostics 10:4, 465-480
CrossRef93
Shmuel Yaccoby. (2010) Advances in the understanding of myeloma bone disease and tumour growth. British Journal of Haematology 149:3, 311-321
CrossRef94
Oliver Lieven, Jürgen Knobloch, Ulrich Rüther. (2010) The regulation of Dkk1 expression during embryonic development. Developmental Biology 340:2, 256-268
CrossRef95
Jason T. Glaw, Thomas C. Skalak, Shayn M. Peirce. (2010) Inhibition of Canonical Wnt Signaling Increases Microvascular Hemorrhaging and Venular Remodeling in Adult Rats. Microcirculationno-no
CrossRef96
Elke Piters, Wendy Balemans, Torben Leo Nielsen, Marianne Andersen, Eveline Boudin, Kim Brixen, Wim Van Hul. (2010) Common Genetic Variation in the DKK1 Gene is Associated with Hip Axis Length but not with Bone Mineral Density and Bone Turnover Markers in Young Adult Men: Results from the Odense Androgen Study. Calcified Tissue International 86:4, 271-281
CrossRef97
Stephanie Byrum, Corey O. Montgomery, Richard W. Nicholas, Larry J. Suva. (2010) The promise of bone cancer proteomics. Annals of the New York Academy of Sciences 1192:1, 222-229
CrossRef98
Dimitrios Daoussis, Andrew P. Andonopoulos, Stamatis-Nick C. Liossis. (2010) Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis. Seminars in Arthritis and Rheumatism 39:5, 369-383
CrossRef99
S. Vallet, S. Mukherjee, N. Vaghela, T. Hideshima, M. Fulciniti, S. Pozzi, L. Santo, D. Cirstea, K. Patel, A. R. Sohani, A. Guimaraes, W. Xie, D. Chauhan, J. A. Schoonmaker, E. Attar, M. Churchill, E. Weller, N. Munshi, J. S. Seehra, R. Weissleder, K. C. Anderson, D. T. Scadden, N. Raje. (2010) From the Cover: Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences 107:11, 5124-5129
CrossRef100
Toni Ibrahim, Emanuela Flamini, Laura Mercatali, Emanuele Sacanna, Patrizia Serra, Dino Amadori. (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:6, 1406-1418
CrossRef101
U. Krause, S. Harris, A. Green, J. Ylostalo, S. Zeitouni, N. Lee, C. A. Gregory. (2010) Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proceedings of the National Academy of Sciences 107:9, 4147-4152
CrossRef102
Mark S Nanes. (2010) Preventing metastases to bone: Denosumab or bisphosphonates?. Journal of Bone and Mineral Research 25:3, 437-439
CrossRef103
Jih-Yang Ko, Feng-Sheng Wang, Ching-Jen Wang, To Wong, Wen-Yi Chou, Shin-Ling Tseng. (2010) Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 46:3, 584-591
CrossRef104
D. Navarro, N. Agra, A. Pestana, J. Alonso, J. M. Gonzalez-Sancho. (2010) The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes -catenin/TCF-mediated transcription. Carcinogenesis 31:3, 394-401
CrossRef105
Ya-Wei Qiang, Yu Chen, Nathan Brown, Bo Hu, Joshua Epstein, Bart Barlogie, John D. Shaughnessy Jr.. (2010) Characterization of Wnt/β-catenin signalling in osteoclasts in multiple myeloma. British Journal of Haematology 148:5, 726-738
CrossRef106
P. Liebisch, J. Drach. (2010) Zytogenetik und Molekularzytogenetik des multiplen Myeloms. Der Onkologe 16:3, 252-262
CrossRef107
Béatrice Bouvard, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand. (2010) Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 77:2, 120-124
CrossRef108
Olivia Lemaire, Michel Attal, Philippe Bourin, Michel Laroche. (2010) DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in Multiple Myeloma. European Journal of Haematology 84:3, 276-277
CrossRef109
Ramón García-Sanz, Adrián Alegre, Francisco Javier Capote, José Mariano Hernández, Laura Rosiñol, Javier de la Rubia, Anna Sureda, Felipe de Arriba, Joan Bargay, Joaquín Díaz Mediavilla, José García-Laraña, Juan José Lahuerta, María Victoria Mateos, Felipe Prósper, Jesús San Miguel, Joan Bladé. (2010) Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología. Medicina Clínica 134:6, 268-278
CrossRef110
X Lu, Y Kang. (2010) Epidermal growth factor signalling and bone metastasis. British Journal of Cancer 102:3, 457-461
CrossRef111
Thomas L. Andersen, Kent Søe, Teis E. Sondergaard, Torben Plesner, Jean-Marie Delaisse. (2010) Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. British Journal of Haematology 148:4, 551-561
CrossRef112
Kenji Kabashima, Jun-ichi Sakabe, Ryutaro Yoshiki, Yasuhiko Tabata, Kimitoshi Kohno, Yoshiki Tokura. (2010) Involvement of Wnt Signaling in Dermal Fibroblasts. The American Journal of Pathology 176:2, 721-732
CrossRef113
Shmuel Yaccoby. (2010) Osteoblastogenesis and tumor growth in myeloma. Leukemia & Lymphoma 51:2, 213-220
CrossRef114
Jochen Schulze, Joachim Albers, Anke Baranowsky, Johannes Keller, Alexander Spiro, Thomas Streichert, Jozef Zustin, Michael Amling, Thorsten Schinke. (2010) Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism. Bone 46:2, 524-533
CrossRef115
Nobuhiro Kamiya, Tatsuya Kobayashi, Yoshiyuki Mochida, Paul B Yu, Mitsuo Yamauchi, Henry M Kronenberg, Yuji Mishina. (2010) Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. Journal of Bone and Mineral Research 25:2, 200-210
CrossRef116
Nicole C. Walsh, Ellen M. Gravallese. (2010) Bone remodeling in rheumatic disease: a question of balance. Immunological Reviews 233:1, 301-312
CrossRef117
Stephanie Byrum, Eric R. Siegel, Sudeepa Bhattacharyya, Larry J. Suva. 2010. Proteomics of Bone Cancer. , 171-180.
CrossRef118
Pierrick G.J. Fournier, Lauren K. Dunn, Gregory A. Clines, Theresa A. Guise. 2010. Tumor-Bone Cell Interactions in Bone Metastases. , 9-40.
CrossRef119
Markus J. Seibel. 2010. Bone Remodeling Markers and Bone Cancer. , 121-135.
CrossRef120
Julia Billiard, John A. Robinson, Ramesh A. Bhat, Bheem M. Bhat, Richard J. Murrills, Peter V.N. Bodine. 2010. Regulation of Osteoblast Differentiation and Bone Cancers by Wnt and PTH Signaling Pathways. , 47-58.
CrossRef121
P GARNERO. 2010. Assessment of Bone Turnover in Men Using Biochemical Markers. , 25-40.
CrossRef122
S V Rajkumar, N M-B Killmann. (2009) Spotlight review series on multiple myeloma. Leukemia 23:1r, R1-R2
CrossRef123
Maria Grano, Giacomina Brunetti, Silvia Colucci. (2009) Immunomodulation of Multiple Myeloma Bone Disease. Clinical Reviews in Bone and Mineral Metabolism 7:4, 293-300
CrossRef124
Apostolos I Gogakos, Moira S Cheung, JH Duncan Bassett, Graham R Williams. (2009) Bone signaling pathways and treatment of osteoporosis. Expert Review of Endocrinology & Metabolism 4:6, 639-650
CrossRef125
Y Zhou, B Barlogie, J D Shaughnessy. (2009) The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 23:11, 1941-1956
CrossRef126
Qing Yi. (2009) Novel Immunotherapies. The Cancer Journal 15:6, 502-510
CrossRef127
Brya Matthews, Tim Cundy. (2009) Paget’s disease of bone. Expert Review of Endocrinology & Metabolism 4:6, 651-668
CrossRef128
Ernesto Canalis. (2009) Growth factor control of bone mass. Journal of Cellular Biochemistry 108:4, 769-777
CrossRef129
Matthew R. Smith, Gordon A. Brown, Fred Saad. (2009) New opportunities in the management of prostate cancer–related bone complications. Urologic Oncology: Seminars and Original Investigations 27:6, S1-S20
CrossRef130
S Deleu, M Lemaire, J Arts, E Menu, E Van Valckenborgh, P King, I Vande Broek, H De Raeve, B Van Camp, P Croucher, K Vanderkerken. (2009) The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 23:10, 1894-1903
CrossRef131
Stefan Bajada, Michael J. Marshall, Karina T. Wright, James B. Richardson, William E.B. Johnson. (2009) Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45:4, 726-735
CrossRef132
Frances Milat, Kong Wah Ng. (2009) Is Wnt signalling the final common pathway leading to bone formation?. Molecular and Cellular Endocrinology 310:1-2, 52-62
CrossRef133
Haibin Zhou, Linshan Shang, Xi Li, Xiyu Zhang, Guimin Gao, Chenhong Guo, Bingxi Chen, Qiji Liu, Yaoqin Gong, Changshun Shao. (2009) Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Experimental Cell Research 315:17, 2953-2962
CrossRef134
B G M Durie, B Van Ness, C Ramos, O Stephens, M Haznadar, A Hoering, J Haessler, M S Katz, G R Mundy, R A Kyle, G J Morgan, J Crowley, B Barlogie, J Shaughnessy. (2009) Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. Leukemia 23:10, 1913-1919
CrossRef135
T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, J. Crowley, B. Barlogie. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:10, 2068-2076
CrossRef136
Patrick Garnero. (2009) Bone markers in osteoporosis. Current Osteoporosis Reports 7:3, 84-90
CrossRef137
A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy, B. Barlogie, S. Yaccoby. (2009) The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 114:9, 1803-1812
CrossRef138
Dimitrios Christoulas, Evangelos Terpos, Meletios A Dimopoulos. (2009) Pathogenesis and management of myeloma bone disease. Expert Review of Hematology 2:4, 385-398
CrossRef139
Yuji Yamaguchi, Akimichi Morita, Akira Maeda, Vincent J Hearing. (2009) Regulation of Skin Pigmentation and Thickness by Dickkopf 1 (DKK1). Journal of Investigative Dermatology Symposium Proceedings 14:1, 73-75
CrossRef140
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage, P. Sonneveld. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology 20:8, 1303-1317
CrossRef141
M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y.-t. Tai, D. Chauhan, C. Mitsiades, R. Prabhala, N. Raje, K. C. Anderson, D. R. Stover, N. C. Munshi. (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:2, 371-379
CrossRef142
Frank J. Secreto, Luke H. Hoeppner, Jennifer J. Westendorf. (2009) Wnt signaling during fracture repair. Current Osteoporosis Reports 7:2, 64-69
CrossRef143
Tomoki Makino, Makoto Yamasaki, Ichiro Takemasa, Atsushi Takeno, Yurika Nakamura, Hiroshi Miyata, Shuji Takiguchi, Yoshiyuki Fujiwara, Nariaki Matsuura, Masaki Mori, Yuichiro Doki. (2009) Dickkopf-1 Expression as a Marker for Predicting Clinical Outcome in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology 16:7, 2058-2064
CrossRef144
Michael J. Marshall, Sally F. Evans, Christopher A. Sharp, Diane E. Powell, Helen S. McCarthy, Michael W.J. Davie. (2009) Increased circulating Dickkopf-1 in Paget's disease of bone. Clinical Biochemistry 42:10-11, 965-969
CrossRef145
L.-H. Weng, C.-J. Wang, J.-Y. Ko, Y.-C. Sun, Y.-S. Su, F.-S. Wang. (2009) Inflammation induction of Dickkopf-1 mediates chondrocyte apoptosis in osteoarthritic joint. Osteoarthritis and Cartilage 17:7, 933-943
CrossRef146
Yiming Zhou, Bijay Nair, John D Shaughnessy Jr, Marie-Astrid Cartron, Jeff Haessler, Elias Anaissie, Frits van Rhee, John Crowley, Bart Barlogie. (2009) Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. British Journal of Haematology 145:5, 637-641
CrossRef147
Yihua Pei, Junko Kano, Tatsuo Iijima, Yukio Morishita, Yukinori Inadome, Masayuki Noguchi. (2009) Overexpression of Dickkopf 3 in hepatoblastomas and hepatocellular carcinomas. Virchows Archiv 454:6, 639-646
CrossRef148
T. Hideshima, D. Chauhan, T. Kiziltepe, H. Ikeda, Y. Okawa, K. Podar, N. Raje, A. Protopopov, N. C. Munshi, P. G. Richardson, R. D. Carrasco, K. C. Anderson. (2009) Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113:21, 5228-5236
CrossRef149
Raymond Poon, Catherine Li, Benjamin A. Alman. (2009) Beta-catenin Mediates Soft Tissue Contracture in Clubfoot. Clinical Orthopaedics and Related Research 467:5, 1180-1185
CrossRef150
Nathalie Voorzanger-Rousselot, Fabrice Journe, Valérie Doriath, Jean-Jacques Body, Patrick Garnero. (2009) Assessment of Circulating Dickkopf-1 with a New Two-Site Immunoassay in Healthy Subjects and Women with Breast Cancer and Bone Metastases. Calcified Tissue International 84:5, 348-354
CrossRef151
Bhoomi Mehrotra. (2009) Bisphosphonates—Role in Cancer Therapies. Journal of Oral and Maxillofacial Surgery 67:5, 19-26
CrossRef152
Y.-W. Qiang, B. Hu, Y. Chen, Y. Zhong, B. Shi, B. Barlogie, J. D. Shaughnessy. (2009) Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling. Blood 113:18, 4319-4330
CrossRef153
Jessica Levy, G. David Roodman. (2009) The role of bisphosphonates in multiple myeloma. Current Hematologic Malignancy Reports 4:2, 108-112
CrossRef154
Nathalie Voorzanger-Rousselot, Delphine Goehrig, Thierry Facon, Philippe Clézardin, Patrick Garnero. (2009) Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. British Journal of Haematology 145:2, 264-266
CrossRef155
Nicolas Josselin, Hélène Libouban, Mamoun Dib, Norbert Ifrah, Erick Legrand, Michel Félix Baslé, Maurice Audran, Daniel Chappard. (2009) Quantification of Dendritic Cells and Osteoclasts in the Bone Marrow of Patients with Monoclonal Gammopathy. Pathology & Oncology Research 15:1, 65-72
CrossRef156
Jingsong Zhao, Kyung-Ah Kim, Arie Abo. (2009) Tipping the balance: modulating the Wnt pathway for tissue repair. Trends in Biotechnology 27:3, 131-136
CrossRef157
G D Roodman. (2009) Pathogenesis of myeloma bone disease. Leukemia 23:3, 435-441
CrossRef158
A. Quintas-Cardama, J. Cortes. (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:8, 1619-1630
CrossRef159
Yan Chen, Benjamin A. Alman. (2009) Wnt pathway, an essential role in bone regeneration. Journal of Cellular Biochemistry 106:3, 353-362
CrossRef160
J. J. Pinzone, B. M. Hall, N. K. Thudi, M. Vonau, Y.-W. Qiang, T. J. Rosol, J. D. Shaughnessy. (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113:3, 517-525
CrossRef161
Angela Pennisi, Xin Li, Wen Ling, Sharmin Khan, Maurizio Zangari, Shmuel Yaccoby. (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology 84:1, 6-14
CrossRef162
K Podar, D Chauhan, K C Anderson. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:1, 10-24
CrossRef163
Ulrike Heider, Martin Kaiser, Maren Mieth, Britta Lamottke, Jessica Rademacher, Christian Jakob, Edgar Braendle, David Stover, Orhan Sezer. (2009) Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. European Journal of Haematology 82:1, 31-38
CrossRef164
Jeroen T. Buijs, Gabri van der Pluijm. (2009) Osteotropic cancers: From primary tumor to bone. Cancer Letters 273:2, 177-193
CrossRef165
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
CrossRef166
B. Barlogie, J. Epstein, J. D. Shaughnessy. (2008) Going with the flow, and beyond, in myeloma. Blood 112:10, 3917-3918
CrossRef167
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy, F. Zhan. (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112:10, 4235-4246
CrossRef168
G David Roodman. (2008) Novel targets for myeloma bone disease. Expert Opinion on Therapeutic Targets 12:11, 1377-1387
CrossRef169
Nicola L. Fazzalari. (2008) Bone remodeling: A review of the bone microenvironment perspective for fragility fracture (osteoporosis) of the hip. Seminars in Cell & Developmental Biology 19:5, 467-472
CrossRef170
I Breitkreutz, M S Raab, S Vallet, T Hideshima, N Raje, C Mitsiades, D Chauhan, Y Okawa, N C Munshi, P G Richardson, K C Anderson. (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:10, 1925-1932
CrossRef171
Georg Schett, Christian Stach, Jochen Zwerina, Reinhard Voll, Bernhard Manger. (2008) How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis & Rheumatism 58:10, 2936-2948
CrossRef172
Donatella Granchi, Serena Rubina Baglìo, Ilaria Amato, Armando Giunti, Nicola Baldini. (2008) Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. International Journal of Cancer 123:7, 1526-1535
CrossRef173
Maripat Corr. (2008) Wnt–β-catenin signaling in the pathogenesis of osteoarthritis. Nature Clinical Practice Rheumatology 4:10, 550-556
CrossRef174
Sonja Zehetmayer, Peter Bauer, Martin Posch. (2008) Optimized multi-stage designs controlling the false discovery or the family-wise error rate. Statistics in Medicine 27:21, 4145-4160
CrossRef175
Christopher L. Hall, Stephanie D. Daignault, Rajal B. Shah, Kenneth J. Pienta, Evan T. Keller. (2008) Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. The Prostate 68:13, 1396-1404
CrossRef176
Georg Schett, Jochen Zwerina, Jean-Pierre David. (2008) The role of Wnt proteins in arthritis. Nature Clinical Practice Rheumatology 4:9, 473-480
CrossRef177
Guojun Bu, Wenyan Lu, Chia‐Chen Liu, Katri Selander, Toshiyuki Yoneda, Christopher Hall, Evan T. Keller, Yonghe Li. (2008) Breast cancer‐derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. International Journal of Cancer 123:5, 1034-1042
CrossRef178
K. K. Dobbin. (2008) A method for constructing a confidence bound for the actual error rate of a prediction rule in high dimensions. Biostatistics 10:2, 282-296
CrossRef179
T. J. Martin, N. A. Sims, K. W. Ng. (2008) Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporosis International 19:8, 1125-1138
CrossRef180
David S. Morris, Scott A. Tomlins, James E. Montie, Arul M. Chinnaiyan. (2008) The discovery and application of gene fusions in prostate cancer. BJU International 102:3, 276-282
CrossRef181
Harry C. Blair, Mone Zaidi, Christopher L.-H. Huang, Li Sun. (2008) The Developmental Basis of Skeletal Cell Differentiation and the Molecular Basis of Major Skeletal Defects. Biological Reviews
CrossRef182
Frank J. T. Staal, Tiago C. Luis, Machteld M. Tiemessen. (2008) WNT signalling in the immune system: WNT is spreading its wings. Nature Reviews Immunology 8:8, 581-593
CrossRef183
G. Clines, L. A. Kingsley. (2008) Novel Targets for and Mechanisms of Bone Metastasis: Meeting Report from Skeletal Complications of Malignancy V: October 25-27, 2007 in Philadelphia, Pennsylvania, USA. IBMS BoneKEy 5:8, 297-301
CrossRef184
C. M. Edwards. (2008) Wnt signaling: bone's defense against myeloma. Blood 112:2, 216-217
CrossRef185
Y.-W. Qiang, J. D. Shaughnessy, S. Yaccoby. (2008) Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112:2, 374-382
CrossRef186
Zhi Gang Li, Paul Mathew, Jun Yang, Michael W. Starbuck, Amado J. Zurita, Jie Liu, Charles Sikes, Asha S. Multani, Eleni Efstathiou, Adriana Lopez, Jing Wang, Tina V. Fanning, Victor G. Prieto, Vikas Kundra, Elba S. Vazquez, Patricia Troncoso, Austin K. Raymond, Christopher J. Logothetis, Sue-Hwa Lin, Sankar Maity, Nora M. Navone. (2008) Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Journal of Clinical Investigation
CrossRef187
Carmen E. Macsai, Bruce K. Foster, Cory J. Xian. (2008) Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. Journal of Cellular Physiology 215:3, 578-587
CrossRef188
Barbara Zdzisińska, Agnieszka Bojarska-Junak, Anna Dmoszyńska, Martyna Kandefer-Szerszeń. (2008) Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Archivum Immunologiae et Therapiae Experimentalis 56:3, 207-221
CrossRef189
L. Ikonomou, E. Geras-Raaka, B. M. Raaka, M. C. Gershengorn. (2008) β-catenin signalling in mesenchymal islet-derived precursor cells. Cell Proliferation 41:3, 474-491
CrossRef190
Martin Kaiser, Maren Mieth, Peter Liebisch, Romy Oberländer, Jessica Rademacher, Christian Jakob, Lorenz Kleeberg, Claudia Fleissner, Edgar Braendle, Malte Peters, David Stover, Orhan Sezer, Ulrike Heider. (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. European Journal of Haematology 80:6, 490-494
CrossRef191
Claire M. Edwards, Junling Zhuang, Gregory R. Mundy. (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42:6, 1007-1013
CrossRef192
Isabelle Broek, Karin Vanderkerken, Benjamin Camp, Ivan Riet. (2008) Extravasation and homing mechanisms in multiple myeloma. Clinical & Experimental Metastasis 25:4, 325-334
CrossRef193
Markus J. Seibel. (2008) The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clinical Endocrinology 68:6, 839-849
CrossRef194
A. A. Morales, D. Gutman, K. P. Lee, L. H. Boise. (2008) BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111:10, 5152-5162
CrossRef195
Ya-Wei Qiang, Bart Barlogie, Stuart Rudikoff, John D. Shaughnessy. (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42:4, 669-680
CrossRef196
Anne K. Mylin, Niels Abildgaard, Julia S. Johansen, Niels F. Andersen, Lene Heickendorff, Therese Standal, Peter Gimsing, Lene M. Knudsen. (2008) High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. European Journal of Haematology 80:4, 310-317
CrossRef197
C. M. Edwards, J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, G. R. Mundy. (2008) Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:5, 2833-2842
CrossRef198
P. Garnero. (2008) New Biochemical Markers of Bone Turnover. IBMS BoneKEy 5:3, 84-102
CrossRef199
C. Gregory. (2008) MM-induced osteolysis: partners in crime. Blood 112:1, 3-4
CrossRef200
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, J. D. Shaughnessy. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:1, 196-207
CrossRef201
Deborah V. Novack, Steven L. Teitelbaum. (2008) The Osteoclast: Friend or Foe?. Annual Review of Pathology: Mechanisms of Disease 3:1, 457-484
CrossRef202
Shi Wei, Gene P Siegal. (2008) Targeting p38 MAPK for the treatment of inflammatory arthritis. Future Rheumatology 3:1, 37-42
CrossRef203
Sundeep Khosla, Jennifer J. Westendorf, Merry Jo Oursler. (2008) Building bone to reverse osteoporosis and repair fractures. Journal of Clinical Investigation 118:2, 421-428
CrossRef204
Z G Li, J Yang, E S Vazquez, D Rose, F Vakar-Lopez, P Mathew, A Lopez, C J Logothetis, S-H Lin, N M Navone. (2008) Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27:5, 596-603
CrossRef205
Mark H. Bilsky, Syed Azeem. (2008) Multiple Myeloma: Primary Bone Tumor with Systemic Manifestations. Neurosurgery Clinics of North America 19:1, 31-40
CrossRef206
Sonia Vallet, Antonio Palumbo, Noopur Raje, Mario Boccadoro, Kenneth C. Anderson. (2008) Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leukemia & Lymphoma 49:7, 1238-1245
CrossRef207
Alfonso Quintás-Cardama, Jorge Cortes, Hagop Kantarjian. 2008. Biology of Chronic and Acute Myeloid Leukemia. , 371-383.
CrossRef208
G. D. Roodman. (2008) Skeletal Imaging and Management of Bone Disease. Hematology 2008:1, 313-319
CrossRef209
N Lee, A J Smolarz, S Olson, O David, J Reiser, R Kutner, N C Daw, D J Prockop, E M Horwitz, C A Gregory. (2007) A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. British Journal of Cancer 97:11, 1552-1559
CrossRef210
Klaus Podar, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson. (2007) The malignant clone and the bone-marrow environment. Best Practice & Research Clinical Haematology 20:4, 597-612
CrossRef211
W.J. Chng, O. Glebov, P.L. Bergsagel, W.M. Kuehl. (2007) Genetic events in the pathogenesis of multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 571-596
CrossRef212
Flavia R. Esteve, G. David Roodman. (2007) Pathophysiology of myeloma bone disease. Best Practice & Research Clinical Haematology 20:4, 613-624
CrossRef213
Bart Barlogie, Elias Anaissie, Frits van Rhee, Mauricio Pineda-Roman, Maurizio Zangari, John Shaughnessy, Joshua Epstein, John Crowley. (2007) The Arkansas approach to therapy of patients with multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 761-781
CrossRef214
Teru Hideshima, Kenneth C. Anderson. (2007) Preclinical Studies of Novel Targeted Therapies. Hematology/Oncology Clinics of North America 21:6, 1071-1091
CrossRef215
M. Corr, N. E. Lane. (2007) FRZB : A bone and joint connection. Arthritis & Rheumatism 56:12, 3881-3883
CrossRef216
Constantine S. Mitsiades, Douglas W. McMillin, Steffen Klippel, Teru Hideshima, Dharminder Chauhan, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson. (2007) The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. Hematology/Oncology Clinics of North America 21:6, 1007-1034
CrossRef217
Suzanne Lentzsch, Lori A. Ehrlich, G. David Roodman. (2007) Pathophysiology of Multiple Myeloma Bone Disease. Hematology/Oncology Clinics of North America 21:6, 1035-1049
CrossRef218
Bingzong Li, Mingxia Shi, Jing Li, Hongbing Zhang, Bin Chen, Lei Chen, Weibo Gao, Nicola Giuliani, Robert Chunhua Zhao. (2007) Elevated Tumor Necrosis Factor- α Suppresses TAZ Expression and Impairs Osteogenic Potential of Flk-1 + Mesenchymal Stem Cells in Patients with Multiple Myeloma. Stem Cells and Development 16:6, 921-930
CrossRef219
G D Roodman. (2007) Treatment strategies for bone disease. Bone Marrow Transplantation 40:12, 1139-1146
CrossRef220
C S Chim, R Pang, T K Fung, C L Choi, R Liang. (2007) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21:12, 2527-2536
CrossRef221
William C Dougall. (2007) RANKL signaling in bone physiology and cancer. Current Opinion in Supportive and Palliative Care 1:4, 317-322
CrossRef222
Sue A Brown, Gregory A Clines, Theresa A Guise. (2007) Local effects of malignancy on bone. Current Opinion in Endocrinology, Diabetes and Obesity 14:6, 436-441
CrossRef223
Giovanni Tonon. (2007) Molecular Pathogenesis of Multiple Myeloma. Hematology/Oncology Clinics of North America 21:6, 985-1006
CrossRef224
S. Schinner, F. Ülgen, C. Papewalis, M. Schott, A. Woelk, A. Vidal-Puig, W. A. Scherbaum. (2007) Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 51:1, 147-154
CrossRef225
Jacob Haaber, Niels Abildgaard, Lene Meldgaard Knudsen, Inger Marie Dahl, Marianne Lodahl, Mads Thomassen, Gitte Birk Kerndrup, Thomas Rasmussen. (2007) Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. British Journal of Haematology 0:0, 071116225528003-???
CrossRef226
Babatunde O. Oyajobi, I. Ross Garrett, Anjana Gupta, Alda Flores, Javier Esparza, Steve Muñoz, Ming Zhao, Gregory R. Mundy. (2007) Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. British Journal of Haematology 139:3, 434-438
CrossRef227
Clara Bueno, Luiz F. Lopes, Pablo Menendez. (2007) Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Blood Cells, Molecules, and Diseases 39:3, 366-368
CrossRef228
T. J. Martin, K. W. Ng. (2007) New Agents for the Treatment of Osteoporosis. International Bone and Mineral Society Knowledge Environment 4:11, 287-298
CrossRef229
Shoso Munemasa, Akira Sakai, Yoshiaki Kuroda, Yoshiko Okikawa, Yuta Katayama, Hideki Asaoku, Tadahiko Kubo, Yoshitaka Miyakawa, Masahiro Serikawa, Tamito Sasaki, Akiro Kimura. (2007) Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not. British Journal of Haematology 139:1, 41-50
CrossRef230
N Rabin, C Kyriakou, L Coulton, O M Gallagher, C Buckle, R Benjamin, N Singh, J Glassford, T Otsuki, A C Nathwani, P I Croucher, K L Yong. (2007) A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 21:10, 2181-2191
CrossRef231
Nancy E. Lane, Michael C. Nevitt, Li-Yung Lui, Patricia de Leon, Maripat Corr, . (2007) Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis & Rheumatism 56:10, 3319-3325
CrossRef232
Iris Breitkreutz, Marc S. Raab, Sonia Vallet, Teru Hideshima, Noopur Raje, Dharminder Chauhan, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson. (2007) Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. British Journal of Haematology 139:1, 55-63
CrossRef233
Teru Hideshima, Noopur Raje. 2007. The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma. , 23-44.
CrossRef234
Alissa Huston, G. David Roodman. 2007. Myeloma Bone Disease. , 45-60.
CrossRef235
Klaus Podar, Irene Ghobrial, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson. 2007. Niches Within the Multiple Myeloma Bone Marrow Microenvironment. , 61-74.
CrossRef236
N Voorzanger-Rousselot, D Goehrig, F Journe, V Doriath, J J Body, P Clézardin, P Garnero. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. British Journal of Cancer
CrossRef237
Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, I. Vlodavsky, L. J. Suva, J. Epstein, S. Yaccoby, J. D. Shaughnessy, B. Barlogie, R. D. Sanderson. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110:6, 2041-2048
CrossRef238
E Terpos, M-A Dimopoulos, O Sezer. (2007) The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21:9, 1875-1884
CrossRef239
Michael J Nemeth, David M Bodine. (2007) Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Research 17:9, 746-758
CrossRef240
Rikio Suzuki, Makoto Onizuka, Minoru Kojima, Masako Shimada, Satomi Fukagawa, Kosuke Tsuboi, Hiroyuki Kobayashi, Ayumi Shintani, Yoshiaki Ogawa, Hiroshi Kawada, Tomomitsu Hotta, Kiyoshi Ando. (2007) Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. British Journal of Haematology 138:5, 624-631
CrossRef241
Sue A. Brown, Theresa A. Guise. (2007) Cancer-associated bone disease. Current Osteoporosis Reports 5:3, 120-127
CrossRef242
S. Vincent Rajkumar, Martha Q. Lacy, Robert A. Kyle. (2007) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Reviews 21:5, 255-265
CrossRef243
J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy, J. Epstein, L. W. Kwak, Q. Yi. (2007) Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110:5, 1587-1594
CrossRef244
Xin Li, Angela Pennisi, Fenghuang Zhan, Jeffrey R. Sawyer, John D. Shaughnessy, Shmuel Yaccoby. (2007) Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. British Journal of Haematology 138:6, 802-811
CrossRef245
E. Terpos, O. Sezer, P. Croucher, M.-A. Dimopoulos. (2007) Myeloma bone disease and proteasome inhibition therapies. Blood 110:4, 1098-1104
CrossRef246
Teru Hideshima, Constantine Mitsiades, Giovanni Tonon, Paul G. Richardson, Kenneth C. Anderson. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 7:8, 585-598
CrossRef247
Mi Hee Kwack, Young Kwan Sung, Eun Jung Chung, Sang Uk Im, Ji Seop Ahn, Moon Kyu Kim, Jung Chul Kim. (2007) Dihydrotestosterone-Inducible Dickkopf 1 from Balding Dermal Papilla Cells Causes Apoptosis in Follicular Keratinocytes. Journal of Investigative Dermatology
CrossRef248
Lisa G. Horvath, Jayne E. Lelliott, James G. Kench, C.-Soon Lee, Elizabeth D. Williams, Darren N. Saunders, John J. Grygiel, Robert L. Sutherland, Susan M. Henshall. (2007) Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. The Prostate 67:10, 1081-1090
CrossRef249
Constantine S. Mitsiades, Nicholas S. Mitsiades, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson. (2007) Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Journal of Cellular Biochemistry 101:4, 950-968
CrossRef250
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, S. Bonomini, M. Crugnola, C. Mancini, E. Martella, L. Ferrari, A. Tabilio, V. Rizzoli. (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:1, 334-338
CrossRef251
Mone Zaidi. (2007) Skeletal remodeling in health and disease. Nature Medicine 13:7, 791-801
CrossRef252
Roland Baron, Georges Rawadi. (2007) Wnt signaling and the regulation of bone mass. Current Osteoporosis Reports 5:2, 73-80
CrossRef253
Sudeepa Bhattacharyya, Stephanie Byrum, Eric R Siegel, Larry J Suva. (2007) Proteomic analysis of bone cancer: a review of current and future developments. Expert Review of Proteomics 4:3, 371-378
CrossRef254
Ramón García-Sanz, María Victoria Mateos, Jesús Fernando San Miguel. (2007) Mieloma múltiple. Medicina Clínica 129:3, 104-115
CrossRef255
Yuji Yamaguchi, Thierry Passeron, Hidenori Watabe, Ken-ichi Yasumoto, Francois Rouzaud, Toshihiko Hoashi, Vincent J Hearing. (2007) The Effects of Dickkopf 1 on Gene Expression and Wnt Signaling by Melanocytes: Mechanisms Underlying Its Suppression of Melanocyte Function and Proliferation. Journal of Investigative Dermatology 127:5, 1217-1225
CrossRef256
Orit Kollet, Ayelet Dar, Tsvee Lapidot. (2007) The Multiple Roles of Osteoclasts in Host Defense: Bone Remodeling and Hematopoietic Stem Cell Mobilization. Annual Review of Immunology 25:1, 51-69
CrossRef257
J Corre, K Mahtouk, M Attal, M Gadelorge, A Huynh, S Fleury-Cappellesso, C Danho, P Laharrague, B Klein, T Rème, P Bourin. (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia
CrossRef258
N C Gutiérrez, E M Ocio, J de las Rivas, P Maiso, M Delgado, E Fermiñán, M J Arcos, M L Sánchez, J M Hernández, J F San Miguel. (2007) Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21:3, 541-549
CrossRef259
Irene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, Teru Hideshima, Constantine Mitsiades, Robert Schlossman, Kenneth C Anderson, Paul Richardson. (2007) Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs 12:1, 155-163
CrossRef260
Davide F. Robbiani, Kaity Colon, Sarah Ely, Scott Ely, Marta Chesi, P. Leif Bergsagel. (2007) Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematological Oncology 25:1, 16-20
CrossRef261
Urszula T Iwaniec, Thomas J Wronski, Jeff Liu, Mercedes F Rivera, Rosemarie R Arzaga, Gwenn Hansen, Robert Brommage. (2007) PTH Stimulates Bone Formation in Mice Deficient in Lrp5. Journal of Bone and Mineral Research 22:3, 394-402
CrossRef262
Peter V Bodine. (2007) Wnt signaling in bone. BoneKEy-Osteovision 4:3, 108-123
CrossRef263
M-A Forget, S Turcotte, D Beauseigle, J Godin-Ethier, S Pelletier, J Martin, S Tanguay, R Lapointe. (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. British Journal of Cancer 96:4, 646-653
CrossRef264
Danielle Diarra, Marina Stolina, Karin Polzer, Jochen Zwerina, Michael S Ominsky, Denise Dwyer, Adelheid Korb, Josef Smolen, Markus Hoffmann, Clemens Scheinecker, Desiree van der Heide, Robert Landewe, Dave Lacey, William G Richards, Georg Schett. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine 13:2, 156-163
CrossRef265
Feng-Sheng Wang, Jih-Yang Ko, Chun-Liang Lin, Hsing-Long Wu, Huei-Jin Ke, Pei-Ju Tai. (2007) Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40:2, 485-492
CrossRef266
Darko Kastelan, Mirko Korsic. (2007) New hopes in the treatment of osteoporosis in men. Future Rheumatology 2:1, 1-4
CrossRef267
Franco Silvestris, Lucia Lombardi, Monica De Matteo, Arianna Bruno, Franco Dammacco. (2007) Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. Leukemia Research 31:2, 129-138
CrossRef268
Dorit Naot, Usha Bava, Brya Matthews, Karen E Callon, Gregory D Gamble, Michael Black, Sarah Song, Rocco P Pitto, Tim Cundy, Jill Cornish, Ian R Reid. (2007) Differential Gene Expression in Cultured Osteoblasts and Bone Marrow Stromal Cells From Patients With Paget's Disease of Bone. Journal of Bone and Mineral Research 22:2, 298-309
CrossRef269
Jinyong Luo, Jin Chen, Zhong-Liang Deng, Xiaoji Luo, Wen-Xin Song, Katie A Sharff, Ni Tang, Rex C Haydon, Hue H Luu, Tong-Chuan He. (2007) Wnt signaling and human diseases: what are the therapeutic implications?. Laboratory Investigation 87:2, 97-103
CrossRef270
Francesco A. Piazza, Carmela Gurrieri, Livio Trentin, Gianpietro Semenzato. (2007) Towards a new age in the treatment of multiple myeloma. Annals of Hematology 86:3, 159-172
CrossRef271
S Schinner, H S Willenberg, D Krause, M Schott, V Lamounier-Zepter, A W Krug, M Ehrhart-Bornstein, S R Bornstein, W A Scherbaum. (2007) Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. International Journal of Obesity
CrossRef272
Christopher L. Hall, Evan T. Keller. (2007) The role of Wnts in bone metastases. Cancer and Metastasis Reviews 25:4, 551-558
CrossRef273
Mark L. Johnson, Nalini Rajamannan. (2007) Diseases of Wnt signaling. Reviews in Endocrine and Metabolic Disorders 7:1-2, 41-49
CrossRef274
Michael E. Mulligan, Ashraf Z. Badros. (2007) PET/CT and MR imaging in myeloma. Skeletal Radiology 36:1, 5-16
CrossRef275
Nicola Giuliani, Vittorio Rizzoli. (2007) Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma. Leukemia & Lymphoma 48:12, 2323-2329
CrossRef276
Carl A. Gregory. (2007) More progress defining the crosstalk between multiple myeloma and mesenchymal stem cells of the bone marrow. Leukemia & Lymphoma 48:10, 1896-1897
CrossRef277
2007. M. , 125-137.
CrossRef278
Laurent Garderet, Christelle Mazurier, Alain Chapel, Isabelle Ernou, Laetitia Boutin, Xavier Holy, Norbert Claude Gorin, Manuel Lopez, Christelle Doucet, Jean-Jacques Lataillade. (2007) Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leukemia & Lymphoma 48:10, 2032-2041
CrossRef279
Ruth Schwaninger, Cyrill A. Rentsch, Antoinette Wetterwald, Geertje van der Horst, Rutger L. van Bezooijen, Gabri van der Pluijm, Clemens W.G.M. Löwik, Karin Ackermann, Walter Pyerin, Freddie C. Hamdy, George N. Thalmann, Marco G. Cecchini. (2007) Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases. The American Journal of Pathology 170:1, 160-175
CrossRef280
J. Stagg. (2007) Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 69:1, 1-9
CrossRef281
Rutger L van Bezooijen, J Peter Svensson, Daniël Eefting, Annemieke Visser, Geertje van der Horst, Marcel Karperien, Paul HA Quax, Harry Vrieling, Socrates E Papapoulos, Peter ten Dijke, Clemens WGM Löwik. (2007) Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation. Journal of Bone and Mineral Research 22:1, 19-28
CrossRef282
C Niehrs. (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:57, 7469-7481
CrossRef283
Evangelos Terpos, Deborah J. Heath, Amin Rahemtulla, Kostas Zervas, Andrew Chantry, Athanasios Anagnostopoulos, Anastasia Pouli, Eirini Katodritou, Evgenia Verrou, Elisavet-Christine Vervessou, Meletios-Athanassios Dimopoulos, Peter I. Croucher. (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology 135:5, 688-692
CrossRef284
Evangelos Terpos. (2006) Antibodies to dickkopf-1 protein. Expert Opinion on Therapeutic Patents 16:10, 1453-1458
CrossRef285
Ji Li, Ildiko Sarosi, Russell C. Cattley, James Pretorius, Frank Asuncion, Mario Grisanti, Sean Morony, Stephen Adamu, Zhaopo Geng, Wanrong Qiu, Paul Kostenuik, David L. Lacey, W. Scott Simonet, Brad Bolon, Xueming Qian, Victoria Shalhoub, Michael S. Ominsky, Hua Zhu Ke, Xiaodong Li, William G. Richards. (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:4, 754-766
CrossRef286
Marianna C. Politou, Deborah J. Heath, Amin Rahemtulla, Richard Szydlo, Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Peter I. Croucher, Evangelos Terpos. (2006) Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer 119:7, 1728-1731
CrossRef287
Mark A Rubin, Arul M Chinnaiyan. (2006) Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Laboratory Investigation
CrossRef288
Miguel H. Bronchud. 2006. Oncology, Molecular. .
CrossRef289
Ulrike Heider, Martin Kaiser, Christian Muller, Christian Jakob, Ivana Zavrski, Carsten-Oliver Schulz, Claudia Fleissner, Monica Hecht, Orhan Sezer. (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology 77:3, 233-238
CrossRef290
Inge Stewart, Claire Roddie, Anthony Gill, Adele Clarkson, Michiko Mirams, Luke Coyle, Christopher Ward, Philip Clifton-Bligh, Bruce G. Robinson, Rebecca S. Mason, Roderick J. Clifton-Bligh. (2006) Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone 39:2, 369-376
CrossRef291
Luis Ramos, Jose Antonio de las Heras, Sergio Sanchez, Jose Ramon Gonzalez-Porras, Rafael Gonzalez, Maria Victoria Mateos, Jesus F. San Miguel. (2006) Medium-term results of percutaneous vertebroplasty in multiple myeloma. European Journal of Haematology 77:1, 7-13
CrossRef292
F Weerkamp, J J M van Dongen, F J T Staal. (2006) Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia 20:7, 1197-1205
CrossRef293
Alissa Huston, G David Roodman. (2006) Role of the microenvironment in multiple myeloma bone disease. Future Oncology 2:3, 371-378
CrossRef294
Frederic Morvan, Kim Boulukos, Philippe Clément-Lacroix, Sergio Roman Roman, Isabelle Suc-Royer, Béatrice Vayssière, Patrick Ammann, Patrick Martin, Sonia Pinho, Philippe Pognonec, Patrick Mollat, Christof Niehrs, Roland Baron, Georges Rawadi. (2006) Deletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass. Journal of Bone and Mineral Research 21:6, 934-945
CrossRef295
Aaron N. Nguyen, Elizabeth G. Stebbins, Margaret Henson, Gilbert O'Young, Sun J. Choi, Diana Quon, Debby Damm, Mamatha Reddy, Jing Y. Ma, Edwin Haghnazari, Ann M. Kapoun, Satyanarayana Medicherla, Andy Protter, George F. Schreiner, Noriyoshi Kurihara, Judy Anderson, G. David Roodman, Tony A. Navas, Linda S. Higgins. (2006) Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research 312:10, 1909-1923
CrossRef296
T. R. Halfdanarson, W. J. Hogan, T. J. Moynihan. (2006) Oncologic Emergencies: Diagnosis and Treatment. Mayo Clinic Proceedings 81:6, 835-848
CrossRef297
Xuguang Nie, Keijo Luukko, Karianne Fjeld, Inger Hals Kvinnsland, Päivi Kettunen. (2006) Developmental expression of Dkk1-3 and Mmp9 and apoptosis in cranial base of mice. Journal of Molecular Histology 36:6-7, 419-426
CrossRef298
Patrizia Tosi, Elena Zamagni, Claudia Cellini, Raffaele Parente, Delia Cangini, Paola Tacchetti, Giulia Perrone, Michela Ceccolini, Paola Boni, Sante Tura, Michele Baccarani, Michele Cavo. (2006) First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. European Journal of Haematology 76:5, 399-404
CrossRef299
Je-Yoel Cho, Won-Bong Lee, Hyun-Jung Kim, Kyung Mi Woo, Jeong-Hwa Baek, Je-Yong Choi, Cheol-Gu Hur, Hyun-Mo Ryoo. (2006) Bone-related gene profiles in developing calvaria. Gene 372, 71-81
CrossRef300
Evangelos Terpos, Athanasios Anagnostopoulos, Efstathios Kastritis, Aristotelis Bamias, Konstantinos Tsionos, Meletios-Athanassios Dimopoulos. (2006) Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. British Journal of Haematology 133:3, 301-304
CrossRef301
James Peter Stewart, John D. Shaughnessy. (2006) Role of osteoblast suppression in multiple myeloma. Journal of Cellular Biochemistry 98:1, 1-13
CrossRef302
Yun Ge, Fenghuang Zhan, Bart Barlogie, Joshua Epstein, John Shaughnessy, Shmuel Yaccoby. (2006) Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology 133:1, 83-92
CrossRef303
John De Vos, Dirk Hose, Thierry Reme, Karin Tarte, Jerome Moreaux, Karene Mahtouk, Michel Jourdan, Hartmut Goldschmidt, Jean-Francois Rossi, Friedrich W. Cremer, Bernard Klein. (2006) Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews 210:1, 86-104
CrossRef304
William G. Gunn, Adam Conley, Lisa Deininger, Scott D. Olson, Darwin J. Prockop, Carl A. Gregory. (2006) A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma. Stem Cells 24:4, 986-991
CrossRef305
Christopher L. Hall, Sona Kang, Ormond A. MacDougald, Evan T. Keller. (2006) Role of wnts in prostate cancer bone metastases. Journal of Cellular Biochemistry 97:4, 661-672
CrossRef306
Toshio Matsumoto, Masahiro Abe. (2006) Myeloma-bone interaction: A vicious cycle. BoneKEy-Osteovision 3:3, 8-14
CrossRef307
Robert L Vessella, Theresa A Guise, Edward S Susman, Larry J Suva, Gregory A Clines, Scott L Kominsky, Kristy L Weber, John M Chirgwin, Laurie K McCauley, Wende Kozlow. (2006) Meeting report from skeletal complications of malignancy IV. BoneKEy-Osteovision 3:3, 15-42
CrossRef308
Franco Silvestris, Paola Cafforio, Nicola Calvani, Monica De Matteo, Lucia Lombardi, Franco Dammacco. (2006) In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia & Lymphoma 47:9, 1921-1931
CrossRef309
Vladimir Lazarevic, Anders Wahlin, Magnus Hultdin, Fenguang Zhan, John Shaughnessy. (2006) Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leukemia & Lymphoma 47:9, 1987-1988
CrossRef310
Evangelos Terpos. (2006) Biochemical markers of bone metabolism in multiple myeloma. Cancer Treatment Reviews 32, 15-19
CrossRef311
E. Schipani. (2006) Meeting Report from the 27th Annual Meeting of the American Society for Bone and Mineral Research: September 23-27, 2005 in Nashville, Tennessee, USA. International Bone and Mineral Society Knowledge Environment 3:1, 29-62
CrossRef312
Ulrike Heider, Lorenz C. Hofbauer, Ivana Zavrski, Martin Kaiser, Christian Jakob, Orhan Sezer. (2005) Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochemical and Biophysical Research Communications 338:2, 687-693
CrossRef313
John Shaughnessy Jr, Fenghuang Zhan, Barthel Barlogie, A.K. Stewart. (2005) Gene expression profiling and multiple myeloma. Best Practice & Research Clinical Haematology 18:4, 537-552
CrossRef314
Claire M Shipman, Babatunde O Oyajobi, Gregory R Mundy. (2005) Advances in the management of myeloma bone disease. Expert Opinion on Pharmacotherapy 6:16, 2781-2791
CrossRef315
Teru Hideshima, Klaus Podar, Dharminder Chauhan, Kenneth C. Anderson. (2005) Cytokines and signal transduction. Best Practice & Research Clinical Haematology 18:4, 509-524
CrossRef316
Hiroshi Yasui, Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson. (2005) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. British Journal of Haematology 0:0, 051220022257014
CrossRef317
E Terpos, D Mihou, R Szydlo, K Tsimirika, C Karkantaris, M Politou, E Voskaridou, A Rahemtulla, M A Dimopoulos, K Zervas. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 19:11, 1969-1976
CrossRef318
Atsushi Suzuki, Shinsuke Iida, Miyuki Kato-Uranishi, Emi Tajima, Fenghuang Zhan, Ichiro Hanamura, Yongsheng Huang, Tsutomu Ogura, Satoru Takahashi, Ryuzo Ueda, Bart Barlogie, John Shaughnessy, Hiroyasu Esumi. (2005) ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 24:46, 6936-6944
CrossRef319
Maurizio Zangari, Dixie Esseltine, Choon-Kee Lee, Bart Barlogie, Francesca Elice, Michael J. Burns, Seung-Hee Kang, Shmuel Yaccoby, Kevin Najarian, Paul Richardson, Peter Sonneveld, Guido Tricot. (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology 131:1, 71-73
CrossRef320
Markus J Seibel. (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nature Clinical Practice Oncology 2:10, 504-517
CrossRef321
Yonghe Li, Guojun Bu. (2005) LRP5/6 in Wnt signaling and tumorigenesis. Future Oncology 1:5, 673-681
CrossRef322
Geertje van der Horst, Steffie M van der Werf, Hetty Farih-Sips, Rutger L van Bezooijen, Clemens WGM Löwik, Marcel Karperien. (2005) Downregulation of Wnt Signaling by Increased Expression of Dickkopf-1 and -2 is a Prerequisite for Late-Stage Osteoblast Differentiation of KS483 Cells. Journal of Bone and Mineral Research 20:10, 1867-1877
CrossRef323
Wee J Chng, Rafael Fonseca. (2005) Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics 6:6, 563-573
CrossRef324
Orhan Sezer. (2005) Myeloma bone disease. Hematology 10:4, 19-24
CrossRef325
David M. Findlay, David R. Haynes. (2005) Mechanisms of bone loss in rheumatoid arthritis. Modern Rheumatology 15:4, 232-240
CrossRef326
Julie R Hens, Kimberly M Wilson, Pamela Dann, Xuesong Chen, Mark C Horowitz, John J Wysolmerski. (2005) TOPGAL Mice Show That the Canonical Wnt Signaling Pathway Is Active During Bone Development and Growth and Is Activated by Mechanical Loading In Vitro. Journal of Bone and Mineral Research 20:7, 1103-1113
CrossRef327
Teresa Morgan, Gerald J. Atkins, Melanie K. Trivett, Sandra A. Johnson, Maya Kansara, Stephen L. Schlicht, John L. Slavin, Paul Simmons, Ian Dickinson, Gerald Powell, Peter F.M. Choong, Andrew J. Holloway, David M. Thomas. (2005) Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor κB. The American Journal of Pathology 167:1, 117-128
CrossRef328
Xuguang Nie. (2005) Dkk1, -2, and -3 expression in mouse craniofacial development. Journal of Molecular Histology 36:5, 367-372
CrossRef329
C Shimazaki, R Uchida, S Nakano, K Namura, S-i Fuchida, A Okano, M Okamoto, T Inaba. (2005) High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19:6, 1102-1103
CrossRef330
Carl A. Gregory, Darwin J. Prockop, Jeffrey L. Spees. (2005) Non-hematopoietic bone marrow stem cells: Molecular control of expansion and differentiation. Experimental Cell Research 306:2, 330-335
CrossRef331
Régis Levasseur, Didier Lacombe, Marie Christine de Vernejoul. (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72:3, 207-214
CrossRef332
Evangelos Terpos, Marianna Politou, Amin Rahemtulla. (2005) The role of markers of bone remodeling in multiple myeloma. Blood Reviews 19:3, 125-142
CrossRef333
B. O. Oyajobi. (2005) Recent Insights into Myeloma Bone Disease. International Bone and Mineral Society Knowledge Environment 2:5, 17-25
CrossRef334
A D Santin, F Zhan, S Cane', S Bellone, M Palmieri, M Thomas, A Burnett, J J Roman, M J Cannon, J Shaughnessy, S Pecorelli. (2005) Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal of Cancer 92:8, 1561-1573
CrossRef335
Michela Mattioli, Luca Agnelli, Sonia Fabris, Luca Baldini, Fortunato Morabito, Silvio Bicciato, Donata Verdelli, Daniela Intini, Lucia Nobili, Lilla Cro, Giancarlo Pruneri, Vincenzo Callea, Caterina Stelitano, Anna Teresa Maiolo, Luigia Lombardi, Antonino Neri. (2005) Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24:15, 2461-2473
CrossRef336
Klaus Podar, Teru Hideshima, Dharminder Chauhan, Kenneth C Anderson. (2005) Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets 9:2, 359-381
CrossRef337
M. Audrey Koay, Matthew A. Brown. (2005) Genetic disorders of the LRP5–Wnt signalling pathway affecting the skeleton. Trends in Molecular Medicine 11:3, 129-137
CrossRef338
Christof Niehrs, Bingyu Mao. (2005) Dickkopf 1. AfCS-Nature Molecule Pages
CrossRef339
T. John Martin, Natalie A. Sims. (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in Molecular Medicine 11:2, 76-81
CrossRef340
Mario N Chamorro, Donald R Schwartz, Alin Vonica, Ali H Brivanlou, Kathleen R Cho, Harold E Varmus. (2005) FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development. The EMBO Journal 24:1, 73-84
CrossRef341
Christopher J. Logothetis, Sue-Hwa Lin. (2005) Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer 5:1, 21-28
CrossRef342
Frank J.T. Staal, Hans C. Clevers. (2005) WNT signalling and haematopoiesis: a WNT–WNT situation. Nature Reviews Immunology 5:1, 21-30
CrossRef343
Jaime O Claudio, A Keith Stewart. (2005) Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma. American Journal of PharmacoGenomics 5:1, 35-43
CrossRef344
Constantine S. Mitsiades, Nicholas Mitsiades, Nikhil C. Munshi, Kenneth C. Anderson. (2004) Focus on multiple myeloma. Cancer Cell 6:5, 439-444
CrossRef345
Lee W. Jones, Kerry S. Courneya, Jeffrey K. H. Vallance, Aliya B. Ladha, Michael J. Mant, Andrew R. Belch, Douglas A. Stewart, Tony Reiman. (2004) Association between exercise and quality of life in multiple myeloma cancer survivors. Supportive Care in Cancer 12:11, 780-788
CrossRef346
R. Bouillon. (2004) Meeting Report from the 26th Annual Meeting of the American Society for Bone and Mineral Research: October 1-5, 2004 in Seattle, Washington, USA. International Bone and Mineral Society Knowledge Environment 1:11, 6-50
CrossRef347
Jennifer J. Westendorf, Rachel A. Kahler, Tania M. Schroeder. (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341, 19-39
CrossRef348
Marianna Politou, Evangelos Terpos, Athanasios Anagnostopoulos, Richard Szydlo, Michael Laffan, Mark Layton, Jane F. Apperley, Meletios-Athanasios Dimopoulos, Amin Rahemtulla. (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology 126:5, 686-689
CrossRef349
Jamieson, Catriona H.M., Ailles, Laurie E., Dylla, Scott J., Muijtjens, Manja, Jones, Carol, Zehnder, James L., Gotlib, Jason, Li, Kevin, Manz, Markus G., Keating, Armand, Sawyers, Charles L., Weissman, Irving L., . (2004) Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML. New England Journal of Medicine 351:7, 657-667
Full Text350
Franco Silvestris, Paola Cafforio, Nicola Calvani, Franco Dammacco. (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology 126:4, 475-486
CrossRef351
Robbiani, Davide F., Chesi, Marta, Bergsagel, P. Leif, . (2004) Bone Lesions in Molecular Subtypes of Multiple Myeloma. New England Journal of Medicine 351:2, 197-198
Full Text352
Keizo Ohnaka, Hiroshi Taniguchi, Hisaya Kawate, Hajime Nawata, Ryoichi Takayanagi. (2004) Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochemical and Biophysical Research Communications 318:1, 259-264
CrossRef353
Roodman, G. David, . (2004) Mechanisms of Bone Metastasis. New England Journal of Medicine 350:16, 1655-1664
Full Text354
(2004) DKK1 in Multiple Myeloma. New England Journal of Medicine 350:14, 1464-1466
Full Text355
(2004) In Brief. Nature Reviews Cancer 4:2, 91-91
CrossRef356
Glass, Donald A. II, Patel, Millan S., Karsenty, Gerard, . (2003) A New Insight into the Formation of Osteolytic Lesions in Multiple Myeloma. New England Journal of Medicine 349:26, 2479-2480
Full Text357
E. Seeman. (2001) Clinical and Basic Research Papers: November and December 2003 Selections. International Bone and Mineral Society Knowledge Environment 1:1, 20040126-0
CrossRef
- Letters
